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Triple-negative breast cancers have fewer treatment options than other 
breast cancers. The overall goal of this research is to identify new 
pharmaceutical targets for triple-negative breast cancer through studies of 
the tumor-promoting crosstalk between tumor and surrounding adipose 
tissue. In paper I, we established extracellular flux analyzer-based 
methodology to evaluate metabolic function of cultured cells, used in 
paper II and III. In paper II, we identified the C1q/TNF-related protein 
family member C1qtnf3 as one of the most upregulated secreted proteins 
in E0771 triple negative breast cancer-associated mouse adipose tissue – 
in particular in the obese setting. Antibody-mediated blockage of 
C1QTNF3 reduced macrophage infiltration in breast cancer-associated 
adipose tissue in mice. In cultured macrophages, C1QTNF3 decreased 
oxidative phosphorylation and enhanced M1-polarization. In paper III, 
we demonstrated that E0771 breast cancer tumors grew faster, associated 
with increased de novo lipogenesis from glucose, if transplanted 
orthotopically into adipose tissue than if transplanted outside adipose 
tissue. Based on our in vitro data, we propose that adipose tissue-
produced lactate triggers the observed increase in de novo lipogenesis in 
the tumor. In conclusion, paracrine interactions between adipose tissue 
and breast cancer involve both immunological and metabolic processes, 
associated with enhanced tumor progression. In the future, we hope that 
pharmaceutical targeting of these interactions, in combination with 
conventional therapy, will improve the survival of breast cancer patients. 
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SAMMANFATTNING PÅ SVENSKA 
Det övergripande målet med vår forskning är att identifiera nya 
behandlingsstrategier för terapiresistent bröstcancer genom att studera 
samspelet mellan tumör och omgivande fettväv.  
Bröstcancer är den vanligaste cancerformen hos kvinnor. Många botas 
idag från sin bröstcancer, men trots betydande medicinska framsteg inom 
detta område utvecklar 10-20% av bröstcancerpatienterna trippelnegativa 
tumörer som inte svarar på hormonell behandling och därför har sämre 
prognos. Unga kvinnor med övervikt löper större risk för att drabbas av 
terapiresistent bröstcancer. Bröstcancer växer i nära anslutning till 
fettväv, och fettväven har i flera studier visat sig utgöra en miljö som 
stimulerar tumörtillväxt. Vår hypotes är således att fettväv, och i 
synnerhet fet fettväv, stimulerar progression av bröstcancer. 
I delarbete I, fastställdes protokoll och cellodlingsförhållanden för 
mätning av cellulär respiration och glykolys med en så kallad 
”extracellular flux analyzer”. En metodik som vi använde för att studera 
metabolismen hos makrofager och metabola effekter av fettväv på 
trippelnegativ bröstcancer i delarbete II respektive III. 
I delarbete II analyserade vi genexpressionsmönstret i tumörassocierad 
och kontrollfettväv i smala och dietinducerat feta möss för att identifiera 
potentiella nyckelprotein/mekanismer för den stimulerade tumörtillväxten 
i fettväv.  Genom denna analys upptäckte vi att tumörnärvaro leder till 
kraftigt ökade fettvävsnivåer av adipokinen C1QTNF3 och att denna 
tumöreffekt förstärktes av fetma. Vidare fann vi att C1QTNF3 bidrar till 
ökad infiltrering av makrofager i fettväven samt att C1QTNF3 sänker 
respirationen och stimulerar proinflammatorisk aktivering av odlade 
makrofager.   
I delarbete III fann vi att bröstcancer i kontakt med fettväv växer 
snabbare än bröstcancer utanför fettväven. Den snabbare tillväxten var 
kopplad till ökad de novo lipogenes dvs. ökad omvandling av glukos till 
fett, vilket är en metabol process som anses essentiell för 
tumörprogression. Våra in vitro data visar att laktat frisatt från fettväven 
skulle kunna förklara den ökade de novo lipogenesen i cancercellerna. 
Sammanfattningsvis involverar samspelet mellan bröstcancer och 
närliggande fettväv både immunologiska och metaboliska processer, 
vilka är associerade med ökad tumörprogression. I framtiden hoppas vi 
att denna forskning leder till nya läkemedel som, i kombination med 
konventionell cancerbehandling som kemoterapi och strålning, förbättrar 
prognosen hos patienter med trippelnegativ bröstcancer.
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INTRODUCTION 
Preface: Obesity is an emerging epidemic whilst having implications for 
cancer prevalence and progression. 
Obesity is caused by an increase in adipose tissue mass due to positive 
energy balance i.e. the caloric intake has over time surpassed the energy 
expenditure. The estimated prevalence of obesity has, according to the 
World Health Organization, tripled since 1975. In 2016, it was reported 
that over 1.9 billion adults worldwide in both developing and developed 
countries, are overweight, and 650 million were obese. Overweight and 
obese individuals sum up to 55% of the population in U.S.A, while most 
countries has a prevalence of 10-30% [1]. Moreover, the global burden of 
obesity was projected to reach 2.16 billion overweight and 1.12 billion 
obese by the year of 2030, highlighting that obesity is an emerging 
challenge to public health as the number of obese people will almost 
double over the course of 14 years [2]. Furthermore, there is a gender 
difference in the prevalence of obesity where females are over-
represented, although in countries of the Organisation for Economic Co-
operation and Development (OECD i.e. high income countries, such as 
Scandinavia and Finland) there is a higher prevalence of obesity in males 
[3]. 
Adipose tissue is the body’s main reservoir for energy storage. However, 
in 1987 the adipose tissue was identified as a major site for the 
production of sex steroids and adipokines, and thereby also regarded as 
an important endocrine organ [4]. A compromised endocrine function is 
often seen in obese individuals contributing to insulin resistance, 
hyperglycemia, dyslipidemia, hypertension, and pro-thrombotic and pro-
inflammatory states, which together often are described as the metabolic 
syndrome [5]. The metabolic syndrome increases the risk of developing 
type 2 diabetes and cardiovascular disease, but also other forms of 
disease such as several forms of cancer including endometrial, colon and 
breast cancer. In fact, several epidemiological studies indicate that there 
is a correlation between obesity/metabolic syndrome and breast cancer 
risk [6-10]. The most well established mechanisms underlying increased 
cancer risk in obesity are alterations in endocrine function such as 
increased levels of insulin/IGF-1 and estrogen, and altered levels of 
adipocyte-derived cytokines (adipokines) [11]. This thesis aims to look 
beyond these endocrine links and to explore the symbiotic relationship 
between breast cancer and neighboring adipose tissue to identify new 
mechanisms underlying tumor progression. 
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BREAST CANCER  
Breast cancer 
In women diagnosed with cancer, breast cancer is the most prevalent 
form alongside cervical cancer, representing 25% of all cancer cases in 
2012 [12, 13]. Moreover, one in ten of all diagnosed cancers worldwide 
are contributable to the female breast, and is one of the most common 
cancer forms with 1.7 million new cases each year. Increased incidence 
and improved treatments may partly explain an increase in prevalence 
and decreased mortality of breast cancer, however, the risk of developing 
breast cancer also relies on a numerous risk factors [14, 15]. These may 
e.g. comprise of age, lifestyle, environmental and socioeconomic status, 
which exerts the most vital role as most breast cancers are sporadic and 
non-familial, whereas hereditary forms (such as BRCA1 and BRCA2) 
only constitute to about 5-10%, although presenting a near certain risk 
(60-80%) of developing breast cancer [16]. Breast cancer, alike many 
other cancers, show a vast span in histological, molecular and functional 
heterogeneity that is reflected upon the wide range of treatment options 
including hormone and targeted treatments such as estrogen receptor 
inhibitor tamoxifen or human epidermal growth factor receptor 2 (HER2) 
antibodies. However, several subtypes lack the presence of hormone 
receptors, thus having fewer treatment options and worse prognosis [17]. 
Breast cancer heterogeneity  
Histological heterogeneity 
The subtyping of breast cancer is based on histological, molecular and 
functional classification. Histological examination assesses the growth 
pattern (type) and the degree of differentiation (i.e. grade). The growth 
pattern is used to broadly categorize breast cancer into two major 
subtypes; in situ carcinoma and invasive carcinoma. In situ carcinomas 
are further sub-classified as either ductal or lobular, while the invasive is 
further divided into seven sub-groups. In situ carcinomas are organized 
into five well known differentiation types; comedo, cribiform, 
micropapilary, papillary while the invasive carcinomas are defined as 
grade 1-3. Thus, the histological examination comprises of 17 types [18]. 
The most common type of carcinoma is ductal invasive carcinomas 
comprising about 50-80% of all carcinomas, while 5-15% of all cases 
comprise of invasive lobular carcinoma. 
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Molecular heterogeneity 
In order to better determine the prognosis and to develop targeted 
therapies, the gene expression profiles of breast cancer tumors have been 
classified by microarray. This classification work led to seven groups; 
claudin low, basal like, HER2 enriched, normal breast like (adipose tissue 
signature) and Luminal A/B. The gene expression analysis added thus 
increased depth to the immunohistochemical analysis allowing for better 
separation of previous subtypes; triple negative (basal), luminal (estrogen 
and progesterone positive) and HER2 positive. This has allowed for 
personalized therapy, and better prediction of disease free survival and 
overall survival [18]. Luminal A is the most common subtype and has the 
best survival rates whereas triple negative breast cancers comprise about 
15-20% of all breast cancer cases and are associated with the poorest 
survival [19-21].   
Functional heterogeneity (intra- and inter-tumor heterogeneity) 
There are clinical traits, such as disease progression in terms of growth, 
metastasis and response to treatment which cannot be explained by the 
subtype. Thus, there is heterogeneity in cell populations within each 
tumor and/or differences between patients. This heterogeneity is proposed 
to arise either from cells with equal tumorigenic potential as a 
consequence of stochastic influences or from cancer stem cells that are 
different from the remaining tumor cells, and responsible for the initiation 
and progression of tumors [22, 23]. Genetic and epigenetic factors, 
stemness and microenvironment heterogeneity as well as the origin of 
tumor cells are thought to play important roles in the development of 
functional heterogeneity [24]. 
Immunological heterogeneity – cold and hot tumors 
Immune cell infiltration within the tumor microenvironment can also be 
used to classify tumors. Tumors can either be defined as 
immunosuppressed or as immune-activated, and this is also referred to as 
immunologically cold or hot tumors. Generally, a cold tumor display low 
infiltration of lymphocytes (CD4
+
 and cytotoxic CD8
+
 T cells) and low 
mutational load (unprovoked), while a hot tumor is defined as the direct 
opposite [25]. Tumors are in general void of cytotoxic lymphocytes and 
in most cases often associated with a higher number of immune-
suppressive cells such as regulatory T cells (FoxP3), and myeloid derived 
suppressor cells (MDSCs) [26]. In addition, there is also an accumulation 
of several other immune cell types such as T helper cell 2 and M2 
macrophages which suppress anti-tumor immunity and promote disease 
progression. In an immunologically hot tumor, anti-tumoral responses are 
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generally functional and associated with accumulation mature dendritic 
cells, natural killer cells and type 1 natural T killer cells, also often 
presenting with a T helper cell 1 response and generation of M1 
macrophages posing anti-tumoral responses [27]. 
In breast cancer, macrophages in many cases, make up 50% of the 
cellular mass and increased macrophage accumulation is associated with 
poor prognosis [28]. These macrophages are thought to originate from 
recruited circulating monocytes from the bone marrow, unlike tissue 
resident macrophages, which predominately are thought to originate from 
yolk-sac progenitors [29]. Tissue resident macrophages depend on self-
renewal and are in most tissues and organs irreplaceable, however, in 
organs such as the gut the embryonically derived macrophage pool is 
over time replaced by circulating monocytes [30]. Similar to the gut, 
macrophages accumulated in tumors, referred to as tumor associated 
macrophages, originate from bone marrow derived monocytes and are 
predominately destined to present with a M2 phenotype [31]. Although 
most evidence, based on gene profiling data, supports the M2 
phenotypical nature of tumor associated macrophages, there are cases 
where tumors are predominated by M1-type macrophages [32]. 
Nonetheless, tumors infiltrated by macrophages present with indicative 
signs of a poor prognostic outcome such as high tumor grade and 
proliferation, as well as low hormone expression (i.e. triple negative 
breast cancer) [33]. Clinicopathological features associated with high 
macrophage infiltration include lymph node metastasis, lack of response 
to neoadjuvant chemotherapy and overall decreased disease-free survival 
[34]. 
Defining the immune landscape of tumors has a high prognostic value 
and may lead to patient specific treatments.  However, current tumor data 
sets lack information related to cellular proportions and heterogeneity 
which makes interpretation difficult [25]. Moreover, discrepancy in 
choice of methodological approaches and definition criteria between 
laboratories adds an additional level of complexity in the assessment of 
tumor associated macrophages.  
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ADIPOSE TISSUE 
The endocrine function of adipose tissue 
White adipose tissue was for long considered to solely serve as a long-
term fuel reservoir; storing energy as triglycerides in the fed state, 
whereas releasing energy as fatty acids and glycerol in the fasted state. In 
1987, this paradigm was challenged upon the discovery of the adipocyte-
produced hormone adipsin, and the capability of adipose tissue to 
produce sex hormones [35, 36]. Subsequently, these findings paved the 
way for the discovery of many adipose tissue-produced cytokines, which 
today are known as adipokines or adipocytokines. These adipokines are 
indeed mainly produced by adipose tissue, but not exclusively. Among 
these adipokines, it was the discovery of leptin and its role in energy 
homeostasis that permanently defined the adipose tissue as an endocrine 
organ back in 1994 [37]. Leptin possesses many effects on energy 
homeostasis and most prominently leptin reduces energy intake while 
increasing energy expenditure. These effects are primarily exerted at the 
level of the brain, but leptin has also effects on peripheral tissues such as 
muscle and pancreas. Beyond the role of leptin in energy homeostasis, 
leptin also regulates immune responses, hematopoiesis, angiogenesis 
[38]. Furthermore, these leptin-mediated processes have been shown to 
be important in wound healing processes [39]. Tumor progression 
displays similarities to wound healing and has been described as a wound 
that never heals [40]. It is therefore not surprising that leptin has been 
shown to play a role in tumor progression, especially in breast cancer [41-
43]. Adipose tissue is not only consisting of adipocytes, but to about 50% 
also of pre-adipocytes, fibroblasts, vascular endothelial cells and various 
immune cells such as macrophages. It should be noted that several 
cytokines/adipokines (such as CCL2, IL-6, IL-1B, TNFA and TGFB and 
plasminogen activator inhibitor 1) that are produced by adipocytes are 
also produced at much higher levels by other adipose tissue-resident cells 
[44, 45]. The adipose tissue secretome is depot-dependent and the 
functions of many adipokines are not fully investigated.  
Adipose tissue and the development of comorbidities 
The metabolic syndrome is a constellation of metabolic abnormalities 
such as central obesity, high blood pressure, high blood sugar, high serum 
triglycerides, and low serum high-density lipoprotein which subsequently 
are well known risk factors for the development of obesity related 
comorbidities such as type 2 diabetes and cardiovascular disease [46-48]. 
The development of comorbidities occurs in part as a consequence of 
pathological adipose tissue expansion where the growing adipose tissue 
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loses its functionality along with increased size. Physiological (normal) 
adipose tissue expansion during weight gain involves optimal immune 
responses leading to sufficient extracellular matrix and vascular 
remodeling that accommodate the growing adipocytes, and is permissive 
for the formation of new adipocytes (adipogenesis)  and a sustained anti-
inflammatory state [49]. In contrast, dysfunctional adipose tissue 
expansion, which frequently is seen in obese individuals, is associated 
with adipocyte hypertrophy, hypoxia, increased levels of reactive oxygen 
species (ROS), chronic inflammation, fibrosis and a decreased ability to 
store excess nutrients. Dysfunctional expansion is also associated with an 
altered adipokine release [4, 50]. All these pathological changes may 
ultimately result in ectopic lipid deposition (lipotoxicity) and systemic 
low grade chronic inflammation that in turn increase the disease risk [51]. 
C1Q tumor necrosis factor (TNF) family 
Adiponectin belongs to the C1Q (complement component 1q) family of 
proteins and is one of the most well studied adipokines and regulates 
whole-body metabolism through its insulin sensitizing and anti-
inflammatory effects [52]. Adiponectin exists in different multimer forms 
(trimer, hexamer and high molecular weight multimer) and can also be 
proteolytically cleaved into a globular form. The structural complexity of 
adiponectin is a result of extensive post-translational modification which 
likely is key to the function of adiponectin. The high molecular weight 
form is suggested to be the most bioactive form of the protein [52]. 
Within the C1Q family is the C1q and tumor necrosis factor related 
proteins (C1QTNF1-15), which thus are paralogs with adiponectin, but 
much less explored and expressed both by adipocytes and stromal 
vascular cells of adipose tissue. Similar to adiponectin, these C1QTNF 
proteins undergo extensive post-translational modification and are 
composed by four distinct domains, a signal peptide at the N-terminal, a 
short variable region, a collagenous domain and a globular domain (the 
C1Q-domain) at the C-terminal (Figure 1). All C1Q members are mostly 
arranged as homotrimers, but C1QTNF proteins can also form 
heterotrimeric proteins by combining with different family members. For 
instance, C1QTNF2 and 9 have been shown to form heterotrimeric 
complexes with adiponectin [53]. Relatively little is known about the 
multimeric structures of C1Q proteins [54].  
Based on structure and sequence homology to adiponectin,  the C1QTNF 
family is thought to be engaged in both metabolic and immunological 
regulation [55]. Indeed, several members (1, 2, 3, 5, 9 and 13) of the 
C1QTNF family have been shown to affect glucose and fatty acid 
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metabolism in adipocytes, liver, myocytes and skeletal muscle [54]. 
Overall, this family of proteins appears to serve to improve glucose 
metabolism and insulin sensitivity thus having anti-diabetic effects.  
Moreover, both C1QTNF3 and 12 have been shown to affect 
inflammatory responses.  
 
Figure 1. The structural organization of the C1QTNF family. (A) Illustrates the 
monomeric domain structure of C1QTNF consisting of signal peptide at the N-terminal, a 
short variable region, a collagenous domain and a globular domain at the C-terminal. (B) 
the homotrimeric structure. (C) The higher order structures such as nona- and dodecamers 
[53]. 
 
C1QTNF3 is an adipokine secreted from adipose tissue 
C1qtnf3 mRNA is predominantly expressed in adipose tissue. Less is 
known about the protein expression, but C1QTNF3 protein is secreted 
and found in the circulation.  
The effect of obesity on circulating levels of C1QTNF3 is inconclusive. 
The levels have been reported to increase in genetically obese leptin 
deficient mice, decrease or not change in dietary obese mice (for which 
were having an abundance in leptin levels), and decrease or in human 
obesity and in patients with type 2 diabetes [56-59]. However, the 
circulating C1QTNF3 levels are about 1000-fold lower than the 
adiponectin levels, which possibly indicates that endogenous C1QTNF3 
exerts auto- or paracrine effects rather than endocrine. [60]. 
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Pharmacological treatment with C1QTNF3 recombinant protein, has been 
shown to reduce serum glucose levels in mice by suppressing 
gluconeogenic enzyme expression in hepatocytes, and enhance oxidative 
phosphorylation (OXPHOS) through expression of peroxisome 
proliferators activated receptor-γ co-activator-1α (and associated 
mitochondrial biogenesis) in neonatal rat ventricular myocytes suggesting 
anti-diabetic effects [59, 61, 62]. Moreover, C1QTNF3 has been shown 
to exert anti-inflammatory and anti-fibrotic effects in e.g. the context of 
collagen-induced arthritis in vivo and LPS-induced inflammation in vitro 
[12, 63-66]. 
C1QTNF3 is also expressed in metastasis-associated fibroblasts and has 
been shown to contribute to the cellular proliferation of osteosarcoma 
cells as well as to promote proliferation and migration of endothelial cells 
in mice, suggesting an important role in tumor progression [67, 68]. 
MACROPHAGES  
Adipose tissue macrophages in obesity and metabolic 
disorders 
Macrophages are crudely categorized into the classically activated M1 or 
the alternatively activated M2 type. In reality, these cells encompass a 
much wider and heterogenic spectrum of phenotypes including M2a 
(activation: IL-4 or IL-13), M2b (activation: IL-1B or LPS), M2c (IL-10, 
TGFB or glucocorticoids) and M2d (activation: toll like receptor agonists 
and adenosine) [69]. In simplicity, the M1 type are pro-inflammatory 
associated with IL-12 production promoting microbiocidal T helper cell 1 
polarization, while the M2 type are anti-inflammatory, and generally 
associated with IL-10 production promoting T helper cell 2 polarization 
and wound healing [70]. 
The M2 subtypes, which are important for tissue repair and angiogenesis, 
are the predominant resident macrophage type in adipose tissue of 
healthy individuals. In obese individuals, M1 type macrophages increase 
associated with improper vascularization, hypoxia and low grade 
inflammation [71]. Furthermore, studies indicate that there are more 
macrophages in visceral than in subcutaneous adipose tissue and it may 
also be a difference in macrophage functionality between men and 
women [72]. The implications for macrophages in the development of 
metabolically associated comorbidities are however difficult to fully 
establish as there is uncertainty whether the inflammatory state is the 
cause or the consequence of metabolic dysregulation [51]. However, one 
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hypothesis is that adipocyte death, as result of too severe hypoxia due to 
adipocyte hypertrophy and insufficient vascularization, attracts 
macrophages [73]. Furthermore, increased fatty acid levels due to 
increased lipolysis and reduced storage capacity of obese insulin resistant 
adipocytes can trigger pro-inflammatory responses via activation of toll 
like receptors in adipose tissue resident macrophages. Such inflammatory 
response can be further aggravated through macrophage release of the 
monocyte chemotactic protein-1 (MCP-1/CCL2) that attracts even more 
macrophages. Ultimately this results in a vicious cycle of macrophage 
infiltration and production of pro-inflammatory cytokines that aggravate 
the insulin resistance [74, 75]. 
Tumor associated macrophages 
One of the major components of a tumor is the leukocyte infiltrate of 
which macrophages are a major part of [31]. Tumor associated 
macrophages are thought to originate from circulating monocytes. 
However, it is still being questioned that within some tissues 
macrophages originate from resident precursors seeded during fetal and 
embryonic development (i.e. yolk-sac progenitors) through self-renewal 
[76]. Regardless of the origin, tumor cells and stromal cells produce 
several chemoattractants such as the notorious CCL2 (as well as CCL5), 
but also by cytokines such as the macrophage colony-stimulating factor 
and members of the vascular endothelial growth factor (VEGF) family 
[77]. Once recruited, these cells are differentiated into macrophages by 
various signals in the tumor microenvironment such as Il-10 and TGFB. 
The macrophages are then generally polarized into an M2-like phenotype, 
although evidence suggests the existence of a M1-like tumor associated 
macrophages [78]. M2-like tumor associated macrophages exerts a very 
versatile role in tumor progression (Figure 2). In brief, these cells can 
exert immunosuppressive effects by inhibiting the cytotoxicity of T and 
natural killer (NK) cells through the production of Il-10 [79]. Moreover, 
M2-like macrophages exhibit a poor antigen-presenting capability 
rendering T cells naïve allowing for immune evasion. This has been 
shown to be further aggravated by induction of programmed cell death 
protein 1 (PD-1) via TNFA and Il-10 which reduces proliferation and 
induces dysfunction of T cells, as well as stimulates the recruitment of 
other immunosuppressive cells such as myeloid derived suppressor cells 
and regulatory T-cells [80]. Beyond the immunosuppressive effects, 
tumor associated macrophages are also able to affect metastasis and 
invasion by the production of epidermal growth factor, VEGF and several 
matrix metalloproteinases (e.g. MMP2 and 9), which serve to remodel the 
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extra cellular matrix and to give rise in new blood and lymphatic vessels 
allowing for extravasation of the primary site [80]. 
 
 
Figure 2. The versatility of tumor associated macrophages in tumor progression [31]. 
 
OBESITY, ADIPOSE TISSUE AND THE LINK TO 
CANCER 
Endocrine links between obesity and increased tumor 
progression 
Several epidemiological studies show that obesity increases the risk for 
several types of cancer. These obesity-associated cancer types are not 
solely confined to highly metabolic organs such as gallbladder, intestine, 
liver and pancreas but includes also many other cancers such as breast 
cancer [81, 82]. For instance, there is a correlation between obesity and 
increased metastatic burden in breast cancer [6-10]. Obesity-associated 
endocrine alterations such as increased levels of insulin-like growth 
factor 1, insulin, estrogen and leptin are the most well-established links 
between obesity and increased tumor progression [11, 81, 83-86].  
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Insulin-like growth factor 
The insulin-like growth factor system is a signaling system that plays a 
crucial role in growth and development of tissues and organs and 
possesses potent mitogenic effects [87, 88]. The role of insulin-like 
growth factor was first discovered of its ability to stimulate 
chondrogenesis (formation of cartilage), but the biological significance 
was rapidly expanded to include stimulation of DNA, proteoglycan, 
glycosaminoglycan and protein synthesis but also serves to regulate 
neuronal proliferation, apoptosis and cell survival [89]. The insulin-like 
growth factor system has been implicated in the development several 
pathological conditions including tumorigenesis [90]. Epidemiological 
evidence shows that high circulating levels of insulin-like growth factor 1 
constitute as a risk factor for the development of several cancers 
including breast cancer. However, the validity of the association between 
insulin-like growth factor 1 and cancer risk has been questioned in some 
human studies [88, 91]. Moreover, it has been shown that cells with 
mutated tumor suppressor gene p53 overexpress the insulin-like growth 
factor 1 receptor leading to increased proliferation [92]. Furthermore, 
insulin-like growth factor 1 receptor signaling can promote cellular 
migration in epithelial and certain breast cancer cell lines by alterations in 
integrin and adhesion complexes (E-cadherin) [93, 94]. 
Estrogen 
Adipose tissue can produce estrogen due to its aromatase activity that 
converts androgen precursors produced from e.g. adrenal glands and 
gonads. There are two main alterations that influence sex hormone 
production by adipose tissue; adiposity and menopause. In 
postmenopausal women, the ovaries stop producing estrogen and adipose 
tissue becomes the main production site resulting in decreased estrogen 
levels. Obesity is associated with increased adipose tissue aromatase 
activity leading to increased estrogen (E1) and oestradiol (E2) levels [36, 
81, 95]. The levels of estrogens and other steroid hormones can be much 
higher in local tissues such as breast fluids. Several epidemiological 
studies serve as evidence for a link between sex hormones and increased 
cancer risk, such as endometrial, breast, uterine, ovarian, and prostate 
cancers [96, 97]. Estrogen signaling can exert mitogenic effect in both 
normal and neoplastic mammary tissues and unbound estradiol may cause 
direct or indirect free-radical-mediated DNA damage, genetic instability, 
and mutations in cells, all of which are hallmarks for cancer development 
[96, 98]. Estrogen signaling may however be most relevant for cancers 
expressing sex hormone receptors (ERα and ERβ) [99]. Furthermore, as 
cancer cells may also require the expression of aromatase, it is not 
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improbable that interplay between cancer cells and normal cells in the 
vicinity, such as fibroblasts or adipocytes can occur both in auto- and 
paracrine manners to promote disease progression [100]. 
Adipokines 
Recent research highlights the potential role of adipokines in tumor 
progression via their effects on e.g. angiogenesis, inflammation, 
proliferation and apoptosis. To date, leptin and adiponectin are the most 
well-studied adipokines with respect to cancer risk. Adiponectin 
modulates several important biological responses such as activation of 
pro-survival pathways, stimulation of angiogenesis and anti-inflammatory 
cytokine production as well as exerting antagonizing effect of leptin 
signaling [101]. Leptin regulates food intake and energy expenditure, but 
also mediates proliferation and inhibition of apoptosis [101, 102]. 
Adiponectin and leptin regulate both innate and adaptive immunity. 
Adiponectin suppresses macrophage M1 activation and promotes M2 
proliferation, while leptin does the exact opposite inducing M1 activation 
[103, 104]. More over adiponectin suppresses the activation of other 
various immune cells involved in innate immunity, such as eosinophils, 
neutrophils, γ δ T cells, natural killer cells, and dendritic cells [104]. The 
differences between adiponectin and leptin are also reflected in the 
adaptive immunity where T helper cells 1 and 2 are promoted accordingly 
to adiponectin and leptin levels and their respective macrophage 
polarization [38, 102]. 
Epidemiological studies have associated low levels of circulating 
adiponectin with an increased risk for several types of cancer, and 
likewise for high circulating levels of leptin [105-109]. Tumor promoting 
effects of adiponectin deficiency has on several levels shown to have 
tumor promoting effects such as tumor formation and proliferation, and 
vice versa for adiponectin administration, which also decreases metastatic 
formation. Interestingly, adiponectin has shown to delay early onset due 
to decreased vascularization and increased apoptosis in mice suggesting 
that effects likely are secondary to initiation [101, 110-112]. 
Both high levels of leptin and leptin receptors have been shown to be 
associated with increased tumor growth and progression. For instance, 
leptin receptors and leptin were found in 83% of human breast cancer 
cases, and this was associated with increased occurrence of distant 
metastasis [113]. 
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Adipose tissue is a tumor-promoting microenvironment 
There are several mechanisms other than the endocrine links (as 
described above) that can explain the connection between obesity and 
increased cancer risk. Adipose tissue with its innate ability for extensive 
vessel and extracellular matrix remodeling can provide a hospitable 
environment for growing tumors. In line with this assumption, intra-
abdominal tumors (e.g. ovarian cancer) often metastasize in an adipocyte-
dominated environment suggesting that adipose tissue is a tumor-
promoting microenvironment [7-9, 114-116]. Moreover, obese 
dysfunctional adipose tissue is associated low grade chronic 
inflammation, fibrosis and hypoxia – pathological processes that can 
trigger tumor progression even further (as outlined below).  
The inflammatory process in obese adipose tissue is mediated by a vast 
array of cytokines produced by the adipocytes or stroma (such as TGFB, 
IL-6, TNFA, and CCL2), leading to infiltration and activation of immune 
cells such as myeloid derived suppressor cells, macrophages, as well as 
fibrosis that may contribute to tumor progression [117, 118]. The 
formation of crown-like structures is a common phenomenon of inflamed 
adipose tissue in obesity. A crown-like structure consists of macrophages 
recruited as a response to the spewing of cellular contents of dying or 
already dead adipocytes, such as lipids, cytokines, damage-associated 
molecular patterns (e.g. fatty acids, ATP, ROS, cholesterol and nucleic 
acids), for which they encircle [119]. Crown-like structures are also 
found in certain cancer forms such as breast cancer [119-121]. The 
consequence of  crown-like structures on cancer can at this stage only be 
hypothesized, but data show that such structures are associated with 
elevated aromatase levels and increased the breast cancer risk in women 
with benign breast cancer disease [122]. Moreover, dying adipocytes can 
be carcinogenic via increased release of ROS leading to increased DNA 
damage and reduce DNA repair and thereby genomic instability in 
surrounding cell types (e.g. cancer cell). Furthermore, in breast cancer 
models as well as in obesity, programmed death-ligand 1 (PD-L1), an 
immune checkpoint ligand is upregulated in myeloid derived suppressor 
cells and sets out to diminish the function of CD8
+
 T cells, which are 
important in immune surveillance [123]. Furthermore, adipose tissue 
fibrosis, defined by excess deposition of extracellular matrix components 
such as fibronectin, laminin and collagens, and desmoplasia [124-127] 
can trigger epithelial-to-mesenchymal transition of cancer cells [128]. 
Crown-like structures has been implicated in the formation of 
desmoplasia. 
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The formation of blood vessels (angiogenesis) is also dysregulated in 
obese adipose tissue. Although tumors in some occasions have the ability 
to become vascularized, vessel function is often aberrant and insufficient 
similarly to that of obese adipose tissue and may provoke inflammatory 
alterations and enhance metastasis [119]. Interestingly,  obese (hypoxic) 
adipose tissue display increased lactate production that can stimulate 
tumor progression (this will be discussed in the next sections) [129].  
More recently, attention has been redirected towards the establishment of 
a metabolic interplay between adipose tissue and cancer, giving rise to 
the metabolic symbiosis paradigm. 
TUMOR METABOLISM 
The Warburg effect 
The Warburg effect, discovered 1924 by Otto Warburg, refers to the 
phenomenon where cancer cells increase their ATP-production via 
aerobic glycolysis rather than the oxidative phosphorylation pathway, 
despite sufficient oxygen supply [130, 131]. Glycolysis is a 100-fold 
faster process than oxidative phosphorylation, but generates much less 
ATP per glucose molecule. The reason for cancer cells undergoing a 
switch towards aerobic glycolysis is still unknown, but several 
hypotheses have been proposed. Consolidating pieces of evidence suggest 
that, although ATP deficiency results in cell cycle arrest or even 
apoptosis, ATP is not a limited resource during cellular proliferation in 
multicellular organisms. Instead, rapid proliferation implies a high 
demand for carbon that is used in macromolecular precursors, such as 
Acetyl-CoA and NADPH, which are used in fatty acid, amino acid and 
nucleotide synthesis [132]. Carbon is most quickly generated from 
glycolysis and from glutamine metabolism.  
Atypical tumor metabolism: fatty acid synthesis and 
glutamine metabolism 
Rapidly proliferating cancer cells’ have a high reliance on acquiring fatty 
acids to build membranes, and most tumors rely on de novo lipogenesis 
as the major source of fatty acids [133]. However, a recent meta study 
shows that less aggressive breast cancer subtypes rely on a balance 
between synthesis and oxidation of fatty acids, whereas more aggressive 
type rely on exogenous uptake as indicated by gene expression data 
[134].  
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Fatty acid synthesis implies that citrate leaves the mitochondria and 
generates Acetyl-CoA through ATP citrate lyase (ACLY), and Acetyl-
CoA is in turn carboxylated to Malonyl-CoA through Acetyl-CoA 
carboxylase (ACC, the rate-limiting step for long-chain fatty acid 
synthesis). Malonyl-CoA and Acetyl-CoA are thereafter used as building 
blocks for long chain fatty acids in a stepwise process catalyzed by fatty 
acid synthase (FASN) (Figure 3) [133, 135-137].  
In order keep metabolic homeostasis during fatty acid synthesis, citric 
acid intermediates need to be replenished. Such replenishment is called 
anaplerosis or anaplerotic flux. Most tumors have an increased glutamine 
catabolism that feeds α-ketoglutarate into the citric acid cycle. This in 
turn can either lead to increased ATP-production through oxidative 
phosphorylation or increase citrate production. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Metabolic pathways used by tumors, highlighting the connection between the 
Warburg effect (glycolysis) and fatty acid metabolism. Glycolysis, regulated by 
hexokinase 2 (HK2) and pyruvate kinase isozymes M1/M2 (PKM2), serves to generate 
substrates such as Acetyl-CoA which are used in the synthesis of fatty acids. The 
synthesis of fatty acids is catalyzed by ACLY, ACC and FASN. ATP production can be 
generated from fatty acid oxidation (although likely not when fatty acid synthesis occurs 
because of malonyl-CoA mediated CPT1 inhibition), which itself can be sustained by 
either exogenously or endogenously produced fatty acids. Anaplerotic flux in forms of 
NADPH feeding into the citric acid cycle (TCA cycle) or by α-ketoglutarate (α-KG) from 
glutaminolysis to maintain cellular energy homeostasis is not depicted in this illustration 
[138].  
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Metabolic interactions 
Cancer cells have been shown to engage in a more complex metabolic 
rewiring by interacting with neighboring cells. Pathophysiological 
interactions include symbiotic nutrient sharing, nutrient competition, and 
metabolite-mediated signaling through G protein-coupled receptors [139]. 
These interactions typically serve the tumor in its growth and 
progression.  
One example of symbiotic nutrient sharing is the so called lactate shuttle 
hypothesis, which implies that lactate generated from glycolytic cancer 
cells can be taken up and used for ATP production in neighboring 
oxidative cancer cells [140]. Such a metabolic exchange is well-
characterized in non-tumor tissues e.g. in the brain between astrocytes 
and neurons. Thus, oxygenated cancer cells may use lactate for ATP 
production and that way glucose are spared for cancer cells in hypoxic 
regions of the tumor [141]. This lactate shuttle paradigm has been further 
elaborated on by the Lisanti group. They propose a so called reverse 
Warburg effect where cancer associated fibroblasts are transformed to 
engage in aerobic glycolysis, thereby feeding surrounding (oxidative) 
cancer cells with lactate and pyruvate [142]. This transformation is not 
only restricted to metabolic changes of fibroblasts, but has also been 
shown to occur in cancer associated adipocytes and immune cells (e.g. 
tumor associated macrophages) [115, 143]. 
Metabolic transformation of cancer associated cells stretches beyond the 
Warburg and reverse Warburg effects. For example, cancer associated 
adipocytes can supply the tumor with nutrients such as fatty acids from 
increased lipolysis (Figure 4) [115]. Tumors may use the exogenously 
derived lipids acquired from adipocytes in e.g. fatty acid oxidation to 
generate ATP or in membrane synthesis. 
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Figure 4. An overview of adipocyte lipid metabolism. Lipolysis is orchestrated by four 
key enzymes for which perilipin-1 (PLIN) and hormone sensitive lipase (HSL) initiate the 
process. Adipose triglyceride lipase (ATGL) hydrolyzes triacylglycerol into 
diacylglycerol which is further hydrolyzed by HSL into monoacylglycerol. 
Monoacylglycerol lipase (MAGL) removes the final fatty acid from the glycerol 
backbone. Malignant tumors typically stimulate adipocyte lipolysis. The resultant fatty 
acids may be used for the cancer cells’ energy requirement or for membrane synthesis 
[115].  
 
IMMUNOMETABOLISM: THE CONNECTION 
BETWEEN METABOLISM AND EFFECTOR 
FUNCTION OF IMMUNE CELLS   
Cellular metabolism of activated immune cells 
The Warburg Effect was initially described as phenomenon solely 
confined to cancer cells. In fact, Warburg had discounted this effect in 
white blood cells, describing it as an artefact. Later on, it was however 
concluded that the Warburg effect also applies to activated white blood 
cells: activation of immune cells is associated with increased aerobic 
glycolysis and reduced oxidative phosphorylation [144]. Indeed, within 
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the last decade, complex interconnections between metabolic pathways 
during immune cell activation have been discovered and thus giving rise 
to the concept of immunometabolism. In essence, Warburg metabolism is 
a key feature of activated immune cells, such phagocytes (i.e. 
macrophages) and some leukocytes, and occurs as a response to e.g. 
hypoxia, nutrient alterations but also danger signals and cytokines [145]. 
There are six key metabolic pathways that are important for survival, 
proliferation and effector function of immune cells: glycolysis, the citric 
acid cycle, the pentose phosphate pathway, fatty acid oxidation, fatty acid 
synthesis and amino acid metabolism [132]. 
Glycolysis and the citric acid cycle 
The main difference between alternatively (M2) and classically (M1) 
activated macrophages is glycolysis. M1 macrophages enhance their 
glycolytic rate following activation. Glycolysis converts glucose into 
pyruvate. Normally, pyruvate is converted in Acetyl-CoA through 
pyruvate dehydrogenases, and the generated Acetyl-CoA then enters the 
citric acid cycle. During hypoxic or at pro-inflammatory conditions, 
HIF1A is activated leading to increased conversion of pyruvate into 
lactate, rather than Acetyl-CoA synthesis and ATP-production via 
oxidative phosphorylation. This effect is in part mediated by HIF1A-
induced expression of pyruvate dehydrogenase kinase 1 (PDK1) [146, 
147].  
In parallel with the difference in glycolysis, the citric acid cycle also 
differs between M1 and M2 macrophages. M1 macrophages present with 
a “broken cycle” that result in the accumulation of citrate and succinate 
(Figure 5). Citrate can be used in the production of nitric oxide and 
prostaglandins, key effector molecules of M1 macrophages. The 
accumulation of succinate inhibits prolyl hydroxylase 1 (PHD1), which in 
turn stabilizes HIF1A and thereby glycolysis and increased Il-1B 
expression [148]. 
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Figure 5. M1 macrophages express a broken citric acid cycle leading to the accumulation 
of citrate and succinate. The accumulation of citrate mediates the production of nitric 
oxide, reactive oxygen species and prostaglandins. Whereas, the accumulation of 
succinate results in the stabilization of HIF1A, which in turn results in a sustained Il-1B 
transcription. Modified from [145]. 
 
The pentose phosphate pathway and the respiratory burst of M1 
macrophages 
The pentose phosphate pathway, being a part of glycolysis, serve two 
functions; to divert intermediates from glycolysis into nucleotide and 
amino acid precursors that are necessary for cell growth and proliferation 
and the generation of NADPH which is used by NADPH oxidases to 
generate reactive oxygen species commonly referred to as the respiratory 
burst (Figure 6) [149]. The respiratory burst is essential for the cytotoxic 
actions of M1 macrophages, and is kept under control by anti-oxidant 
enzymes that prevent excessive tissue damage during inflammatory 
responses [150]. NADPH can also be used to synthesize fatty acids which 
can be used in e.g. cellular signaling processes that are important for 
effector function of immune cells [151]. Furthermore, reactive oxygen 
species are also important regulators of cell functions via so called redox 
signaling (reviewed in [150]). 
The respiratory burst is regulated by the carbohydrate kinase-like protein  
(CARKL), an enzyme that limits substrate entry to the pentose phosphate 
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Respiratory Burst
CARKL
pathway from glycolysis and is highly expressed in M2 macrophages and 
is thus a key regulator of the macrophage phenotype [152]. 
 
Figure 6, In immune cells such as macrophages, metabolic pathways can be diverted to 
support effector functions. In this example, the pentose phosphate pathway utilizes 
glucose to generate intermediates such ribose-5-phosphate used in DNA and RNA 
synthesis, and NADPH that can be used in fatty acid synthesis and in the respiratory burst. 
Modified from [153]. 
 
Amino acid metabolism 
The difference in effector function between M1 and M2 macrophages are 
reflected on their difference in arginine metabolism. Arginine acts as a 
substrate for two key enzymes inducible nitric oxide synthase 
(iNOS/NOS2) and arginase 1. NOS2 is highly expressed in M1 
macrophages and converts arginine into nitric oxide (NO) and citrulline. 
Moreover, the cytotoxic activity of M1 macrophages relies in part on 
reactive nitrogen species (e.g. N2O3, peroxynitrite or nitronium ion) that 
are generated from NO. Citrulline is recycled into arginine [154, 155]. 
M2 macrophages express high levels of arginase that generates ornithine 
and urea and limit the availability of arginine for NOS2. Ornithine is 
important in downstream pathways for cellular proliferation and tissue 
repair [154].  
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METABOLISM AS A THERAPEUTIC TARGET IN 
CANCER 
Targeting tumor metabolism  
Cancer cells typically display a high dependence on aerobic glycolysis, 
fatty acid synthesis and glutaminolysis, although the progression of some 
cancers depends on fatty acid oxidation. These metabolic pathways are 
linked to therapeutic resistance and represent thus potential targets for 
cancer treatment [137].  
Indeed, there is a wide range of drugs that target e.g. glycolysis, the citric 
acid cycle and fatty acid synthesis, that are used in cancer therapeutics 
[137]. In brief, glycolysis can be inhibited by targeting glucose 
transporters (Glut 1 or 2) as well as other key enzymes such as 
hexokinase, pyruvate kinase isozymes M1/M2 and lactate dehydrogenase 
A (Table 1). Inhibition of glucose transporters decreases glucose uptake 
thus lowering glycolytic rate and generation of ATP and ultimately 
cellular growth. The use of several drugs targeting the same glucose 
transporters can result in a higher anti-cancer effect by overcoming a 
hypoxia-conferred drug resistance that generally occurs in tumors [137]. 
Hexokinase inhibitors such as 2-DG and 3-BrPa and LND are used in 
pre-clinical and early phase clinical trials of prostate cancer, intracranial 
metastases, and benign hyperplasia, respectively for 2-DG and LND. 3-
BrPa has been studied in hepatocarcinoma (animal model) [156]. These 
substances have similar effects on glycolysis to glucose transporters, but 
have only been shown to have substantial effects in combination of other 
treatments such as radio- or chemotherapy in various different cancer 
types in vitro. Combinatorial treatments for both 2-DG and LND has 
been shown to effective in sensitization to cell death of several cancer 
types including breast cancer cells [156]. PKM2 is another rate limiting 
enzyme of the glycolytic pathway having four isoforms and being 
differentially expressed among cell types, whereas PKM2 is 
predominantly expressed in tumors cells. Changes in PKM2 expression 
has been correlated with drug resistance in human ovarian cancer and 
gastric carcinoma cell lines, and in patients with colorectal cancer; a 
decreased PKM2 protein activity is linked to cisplatin resistance in 
human gastric carcinoma cells, whereas suppression of PKM2 expression 
by siRNA can increase the resistance to cisplatin [157]. The therapeutic 
efficacy has been shown to  be improved by targeting PKM2 with shRNA 
and increasing apoptosis and inhibition of proliferation in a human A549 
xenograft lung cancer model, however, the mechanism of action remains 
to be elucidated and highlights importance of patient specific therapy 
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[158]. Lastly, targeting lactate dehydrogenase, an enzyme catalyzing the 
last step of glycolysis (pyruvate and NADPH to lactate and NAD
+
) has, 
as previously discussed, been shown to be a promising therapeutic target. 
Knockdown of lactate dehydrogenase in human lymphoma (P493 human 
lymphoma B cells) and pancreatic cancer (P198 human pancreatic cancer 
cells) xenografts resulted in increased oxidative phosphorylation, 
decreased ability to withstand hypoxic conditions and decreased 
proliferation [159]. Overall, this results in increased generation of 
reactive oxygen species leading to apoptosis and reduced tumor growth 
[137]. 
Besides glycolysis, metabolic pathways stimulating fatty acid synthesis 
are important in proliferating cancer cells and are therefore also subjects 
for the development of new cancer therapeutics. For instance, there are 
several compounds that display anti-tumoral effect through inhibition of 
fatty acid synthase, an enzyme that is overexpressed in many breast 
cancers and thus a therapeutic target (Table 1). Inhibition of fatty acid 
synthase results in apoptosis by e.g. accumulation of malonyl-CoA, p53 
accumulation, induction of endoplasmic reticulum stress and suppression 
of DNA replication [137]. Inhibition of fatty acid synthase has also been 
shown to affect the formation of lipid rafts through phospholipid 
partitioning thus resulting in the internalization and degradation of human 
epidermal growth factor receptor ErbB2 (HER2) in breast cancer, which 
is suggested to potentiate the anti-tumoral effects of trastuzumab. 
Targeting glutaminolysis, is a two-part process. Glutamine is first 
converted into glutamate by glutaminase and thereafter glutamate is 
converted into α-ketoglutarate by glutamate dehydrogenase. Inhibition of 
glutaminolysis inhibits anaplerotic flux of the citric acid cycle leading to 
reduced generation of ATP through oxidative phosphorylation and/or 
reduced biosynthesis (e.g. fatty acid synthesis). Furthermore, the 
mTORC1 signaling pathway that drives cellular growth is co-induced by 
glutamine and leucine metabolism. The mTOR pathway has also been 
shown to be involved in cisplatin resistance in highly malignant gastric 
cancer cells. Inhibition of glutaminase results in decreased proliferation 
and increased hypoxia-induced cell death. However, sole inhibition of 
glutaminase can increase glycolysis. Therefore, simultaneous inhibition 
of both glutaminolysis and glycolysis is more effective [137]. 
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Metabolic targets in breast cancer 
The standard therapeutic targets for breast cancer accounts for the 
molecular heterogeneity within the subtypes, and thus includes endocrine 
therapy for estrogen receptor-alpha positive and human epidermal growth 
factor receptor-2 enriched, and general chemotherapy for triple negative 
subtypes [160]. The metabolic phenotype of breast cancer is likely 
dependent on the breast cancer subtype, its metastatic stage (i.e. primary, 
disseminated and metastatic tumor) and location. Signaling through the 
estrogen receptor α and estradiol has been shown to being able to 
reprogram metabolism based on the glucose availability. In circumstances 
of high glucose availability, estradiol has been shown to enhance 
glycolysis and suppress oxidative phosphorylation, whereas the opposite 
during conditions of low glucose availability [161]. The estrogen receptor 
α itself has been shown to regulate HIF1A and thus suggest an indirect 
action in activation of glycolysis [162]. In addition, both the estrogen 
receptor α and estradiol are involved in regulating nuclear and 
mitochondrial genes encoding proteins involved in mitochondrial 
function. Meanwhile, the estrogen receptor β has been suggested to exert 
similar effects on glucose metabolism; knockdown of estrogen receptor β 
led to a diminished expression of glycolytic genes, while enhancing the 
expression of genes involved in oxidative phosphorylation [160]. 
Furthermore, human epidermal growth factor receptor-2 enriched tumors 
express higher levels of genes involved in oxidation, storage and 
synthesis of fatty acids in comparison to other subtypes (in addition to 
their reliance on glycolysis) [163]. On the other hand, the importance of 
oxidative phosphorylation associated with an increased susceptibility to 
fatty acid oxidation inhibitors has recently been highlighted in triple 
negative breast cancer [160]. Furthermore, based on mRNA expression 
data triple negative breast cancers rely on the utilization of exogenously 
derived fatty acids as opposed to reliance on de novo lipogenesis [134]. 
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Table 1. Therapeutic drugs used to target metabolic pathways in cancer [137]. 
 
Targeting metabolic pathways in immune cells 
Metabolic pathways in immune cells serve also as targets in the 
development of better cancer treatments as well as in many other 
conditions where regulation of immune responses plays a key role [164]. 
As previously discussed, the preferred metabolic pathways within an 
immune cell determine its phenotype and effector function. Moreover, the 
availability of metabolites may also be crucial for regulating the 
metabolic and phenotypic fate of immune cells [165]. In essence, there 
are two strategies that have been used to target metabolic pathways in 
immune cells; 1) adoptive cellular immunotherapy, and 2) metabolic 
reprogramming of the host.  
Adoptive cellular immunotherapy involves naturally or engineered cells 
such as lymphocytes originating from the resected tumor itself or by the 
engineering of T cells derived from peripheral lymphocytes. These cells 
can then be modified ex-vivo and thereafter re-introduced into the patient, 
which generates a T cell population that has a higher replicative capacity 
and is apathetic to differentiation thus persisting for longer and increasing 
the therapeutic efficiency [165]. While the fortitude of metabolic 
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reprogramming as a therapeutic strategy remains to be elucidated, it has 
been shown that augmentation of OXPHOS and fatty acid oxidation in 
CD8
+
 T cells improved longevity and anti-tumor immunity in-vivo [166]. 
Metabolic reprogramming was conceived as a viable approach as several 
pharmaceutical treatments, such as metformin, have been shown to 
disrupt the electron transport chain (OXPHOS) by inhibiting complex I 
[165]. Other agents such as CPT-1a inhibitors that inhibits fatty acid 
oxidation, and rapamycin that lowers mTOR activity, which functions to 
integrate signaling pathways involved in many pathways affecting cell 
growth, proliferation, and metabolism. Both metformin and rapamycin 
has been shown to act as immunosuppressants by reducing the formation 
of cytotoxic CD8
+
 effector cells and instead stimulate the formation of 
CD8
+
 memory T cells. Collectively, the exerted metabolic effects of 
metformin, rapamycin and CPT-1a inhibitors (etomoxir or perhexiline) 
have been shown to affect T cells and may prove useful in in the 
treatment of several immunity driven diseases such as graft versus host 
disease and cancer. However, as activated T cells and cancer cells often 
share similar metabolic traits, targeting cellular metabolism may serve to 
positively impact tumor progression by means of negatively impact 
infiltrating effector T cells [165, 167]. 
Moreover, metabolites conjugated with pharmaceutical agents can 
potentially be used to target specific immune cell types via transported-
facilitated drug uptake [165]. One example is exploiting cells engaging in 
glycolysis by conjugating a pharmaceutical agent to D-glucose which 
then is taken up via glucose transporters (such as Glut1). This strategy 
has so far resulted in a phase III clinical trial using glufosfamide with D-
glucose to treat patients with metastatic pancreatic adenocarcinoma 
which previously had undergone treatment gemcitabine [168]. Similarly, 
D-glucose has also directly been used to target metabolism by inhibiting 
lactate dehydrogenase through an N-hydroxyndole-based compound 
[165].  
Tumor associated macrophages have been identified to exist as both M1-
like MHC-II
high
 and a M2-like MHC-II
low
 populations, even within the 
same tumor [78]. However, M2-like tumor associated macrophages are 
currently the most plausible therapeutic target as they have been shown to 
affect the efficacy of anticancer treatments, contribute to therapy 
resistance and to mediate tumor relapse [169]. Inhibition of monocyte 
recruitment by blocking CCL2 has been shown to reduce tumor 
progression in many different cancers. However, blocking CCL2 can also 
result in accelerated metastasis through increased cell motility and 
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angiogenesis in breast cancer [170]. Therefore, new strategies targeting 
the repolarization of macrophages through altered metabolism are 
currently being investigated. There are a couple of key studies on this 
topic that is briefly presented in this section:  
1) Tumor derived lactate has been shown activate G 
protein-coupled receptor 132 (GPR132) leading to M2 
polarization of tumor associated macrophages through 
stabilization of HIF1A and the induction of Vegfa, Arg1, 
Relma, Mgl1 and Mgl2 gene expression [171]. Silencing 
of Gpr132 in macrophages reduces cancer growth in 
vitro  and E0771 breast cancer tumor growth is reduced 
in whole-body GPR132 knockout mice [172, 173].  
 
2) The metastasis promoting effect of tumor associated 
macrophages in an in vitro model of pancreatic ductal 
adenocarcinoma was successfully inhibited by 2-
deoxyglucose treatment [174].  
 
3) Inhibition of mTOR activity by rapamycin has been 
shown to stimulate the M1-phenotype and thus enhance 
the macrophages’ anti-tumoral effects in the Huh-7 
hepatocarcinoma cell line in a nude mouse model [175]. 
Moreover, genetic deletion of REDD1 (an inhibitor of 
mTOR) in macrophages results in an increased glucose 
uptake and enhanced glycolysis, further linking the 
metabolic reprogramming to effector function. This 
ultimately results in nutrient competition between the 
tumor associated macrophages and endothelial cells 
preventing vessel leakiness and metastasis [176].  
In summary, altering macrophage phenotypes through metabolic 
reprogramming appears like a promising therapeutic approach in cancer.  
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AIM 
A growing body of research shows that adipose tissue is a tumor-
promoting microenvironment. Furthermore, tumor progression is 
enhanced in obesity and highly associated with altered metabolic 
(mitochondrial) function. The overall goal of this research is to identify 
new targets for the treatment of triple negative breast cancer through 
studies of the paracrine interactions between lean or obese adipose tissue 
and tumor in breast cancer progression.  
SPECIFIC AIMS 
1) Identify new adipose tissue-derived secreted proteins that are 
involved in the paracrine interactions between lean or obese 
adipose tissue and breast cancer. 
a. Set up breast cancer models in vivo and in vitro (paper II 
and III). 
b. Set up methodology to study mitochondrial function in 
cultured cells (paper I, II and III) 
c. Test whether identified secreted protein is involved in 
breast cancer progression and/or tumor immunity (paper 
II). 
2) Proliferating cells require increased amounts of lipids to 
build new membranes. 
a. Test whether increased supply of exogenous lipids via 
breast cancer-induced lipolysis play a role in the tumor-
promoting effect of adipose tissue (paper III). 
b. Test whether adipose tissue alters tumor metabolism and 
whether such alteration is causally linked to the tumor-
promoting effect of adipose tissue (paper III). 
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METHODOLOGICAL CONSIDERATIONS 
MOUSE MODELS OF BREAST CANCER 
Breast cancer is a heterogeneous disease, and its progression include 
different stages; initiation, invasion and metastasis. In order to address 
specific aspects of the disease processes such as elucidating underlying 
molecular pathways it is critical to generate and/or select the most 
appropriate model. There are essentially three different types of mouse 
models for breast cancer research; chemically-induced, genetically-
induced and xenograft breast cancer models [177]. 
The link between chemicals and carcinogenesis was discovered more 
than 200 years ago and has initially been implemented in animals to 
assess the possible carcinogenic effects of low-dose exposure of 
environmental chemicals. Chemical carcinogens, usually agents that 
directly damages DNA, include e.g. polycyclic aromatic hydrocarbons, 
aromatic amines, N-nitroso compounds, alkylating agents and radiation. 
In breast cancer research, N-methyl-N-nitrosourea (MNU) and 7,12-
Dimethylbenz(a)anthracene (DMBA) are the most commonly used agents 
to induce breast cancer because of their relatively high reproducibility 
and these models are used to study tumor initiation and growth in 
immuno-competent mice and rats. Treatment with MNU or DMBA leads 
to hormone dependent tumors, but MNU-induced tumors are largely 
adenocarcinomas while DMBA-induced tumors frequently are benign 
fibroadenomas. 
Genetically engineered mouse models are used to address early events in 
carcinogenesis and have, just like chemically-induced models, the 
advantage of producing tumors in their correct microenvironment. Based 
on knowledge from human tumors, mice can be engineered to study 
effects of specific genes/mutations. Gene promoters such as mouse 
mammary tumor virus (MMTV), whey acidic protein (WAP), C3, B-LG 
and MT can be used to differently express onco- and tumor-suppressor 
genes in the mammary tissues. However, incomplete characterization of 
promoters, and the modification of onco- and tumor-suppressor genes 
that may not completely represent those observed in human tumors, can 
lead to breast cancer models that do not fully represent the human setting. 
In addition, it can be a combination of multiple genes (gene mutations) 
that contribute to carcinogenesis [178]. Moreover, a key drawback in 
using genetically engineered mice is in the study of metastatic disease; 
the penetrance of metastasis is low and requires relatively long time to 
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develop. Thus, large cohorts of mice are necessary and results that e.g. a 
new treatment may not reflect the human situation [178]. Furthermore, 
genetically engineered breast cancer mouse models usually present with 
lung metastasis whereas in humans metastasis are most commonly seen 
in the lymph nodes [179]. 
Unlike chemically induced and genetically engineered breast cancer 
mice, transplant models are by far the most commonly used models for 
breast cancer. There are three different types of transplant models; 
patient-derived cell-line derived xenografts (CDX), patient-derived 
xenografts (PDX), and mouse-derived syngeneic cell lines. These models 
are used to study breast cancer genetics, biological processes and 
metastatic disease, but have a poor record of predicting clinical efficacy 
[178]. Depending on the site of transplantation different stages and organ 
specific metastasis can be assessed, e.g. direct implantation orthotopically 
or ectopically allows for the assessment of metastatic disease as a 
consequence of primary tumor outgrowth. Whereas, injection into the 
circulatory system allows for direct assessment in different organs 
commonly metastasized in humans such as lungs, liver and bone 
dependent on the choice of entry, i.e. tail vein, portal vein or intracardiac 
infusion [180]. 
CDX models originate from highly malignant and metastatic tumors or 
through plural effusion (drained lung fluid) that are cultured and 
domesticated in a non-native in vitro niche aberrant to symbiotic 
interactions in the microenvironment, thus losing its heterogeneity. The 
CDX is then to be transplanted in an immune-suppressed mouse model 
where it rarely metastasizes making it difficult to assess metastatic 
disease, immune interaction and therapeutic efficacy. Some of these 
shortcomings were sought to be addressed with the development of 
PDXs, which involves transplantation of tumor pieces derived from the 
patient. Indeed, PDX has been shown to be more effective in modeling 
metastatic disease. Moreover, human cells are not adapted to grow in a 
murine environment, but tumor pieces include stromal cells leading to 
enhanced tumor progression compared to CDX. Nevertheless, the 
establishment of a PDX is relatively slow and may have limited use for 
the establishment of personalized treatments [178]. Lastly, in order to 
overcome the lack of immune responses, cell lines from spontaneously 
derived mammary tumors of the mouse have been developed. The 
downsides with syngeneic mouse models are that they do not represent 
human breast cancer and that there are very few available models (and all 
are hormone independent); EMT-6, E0771, HCC70 and 4T1 [181, 182]. 
Thus, human xenografts are indispensable for preclinical testing of drugs. 
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However, hormone receptor assessment is not a trivial procedure as the 
occurrence of both hormone negative and positive cells may exist within 
the same tumor. The overall assessment of the hormone receptor status is 
achieved by counting (i.e. scoring) the number of hormone expressing 
cells present in a tumor sample and is expressed as a percentage, and this 
heterogeneity is why some mouse models of human breast cancer can be 
considered belonging to one subtype although they do not [183]. 
The E0771 syngeneic breast cancer model 
The E0771 breast cancer cell line originates from a female C57BL/6 
mouse harboring a spontaneous mammary adenocarcinoma back in 1951 
[184]. The E0771 breast cancer cell line is described as highly aggressive 
and readily colonizes distant locations such as lungs, intestinal mesentery 
and pancreas which makes it suitable model in different stages of cancer 
progression [185]. E0771 breast cancer tumors display a low infiltration 
of lymphocytes such as CD4 and CD8 T cells accompanied by a high 
infiltration of MDSCs, and M2 over M1 polarization of macrophages 
[186, 187]. This leukocyte profile is known to promote tumor growth 
associated with poor prognosis [188, 189]. It is however difficult to 
subtype breast cancers based on the immune infiltrate (only few studies 
are available), but functional and molecular characterization has defined 
E0771 breast cancer as hormone negative [190]. This is of particular 
importance since those breast cancer subtypes do not respond to 
endocrine therapy, resulting in worse outcome and survival for the 
patients than for other subtypes of breast cancer [191]. This model may 
therefore be a suitable tool to delineate novel therapy strategies for triple 
negative cancers – the focus of this thesis.  
MACROPHAGE MODELS 
In the early development, tissue resident macrophages originate from 
yolk-sac progenitors whereas in certain tissues are replaced over time by 
bone marrow derived progenitors [29]. Yolk-sac derived macrophages 
differ in the sense that replenishment occurs through self-renewal and are 
specifically presenting with phenotypes adapted for a specific tissue 
environment, making tissue-resident macrophages a very heterogeneous 
population. The occurrence of temporal heterogeneity may also result 
from infiltration of macrophages of hematopoietic derived cells, during 
e.g. inflammation. There is uncertainty whether or not such cells are 
retained long term after resolution as there are no reliable markers that 
can distinguish between yolk-sac and monocyte derived cells [192]. 
However, it has been shown that ablation of resident macrophages can be 
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compensated by infiltration of bone marrow derived cells and that these 
undergo phenotypic adaptations to become tissue resident macrophages 
[193, 194].  
Primary mouse macrophages can be obtained directly from e.g. tissues, or 
from exfiltration through provocation of the immune system, as well as 
from differentiation of monocyte precursors. The most common origins 
used to isolate monocytes and macrophages are bone marrow, spleen and 
the peritoneum. There are also three commonly used mouse cell lines, IC-
21, RAW264.7 and J774.2 along with several human cell lines. The 
phenotype varies between these models, which warrants for selection of 
the most appropriate macrophage model for the given research question. 
Bone marrow-derived macrophages are advantageous by means of 
representing a homogenous population with a long lifespan and a high 
proliferative capacity. These macrophages and are thus commonly 
selected when large numbers of cells are needed [195]. Whereas 
macrophages derived from tissues are more heterogeneous [29, 195, 196]. 
Cell lines represent cells of higher maturity (i.e. differentiation) than 
primary cells, while splenic and peritoneal has a higher grade of maturity 
than bone marrow-derived macrophages [195]. Bone marrow-derived 
macrophages share many similarities with RAW264.7 in terms of cell 
surface receptors and immune responses. These cells are expressing high 
levels of F4/80 and CD11b, while CD14 expression is higher in the 
RAW264.7 cell line. In contrast, splenic macrophages express very low 
levels of F4/80, CD11b and CD14 [196]. CD14 is important in generating 
T helper cell 1 mediated responses and RAW264.7 cell line may thus be 
more prone to present a M1 phenotype that other models. Furthermore, 
phenotypic differences exist between the primary macrophages in the 
expression of co-stimulatory molecules such as CD80, CD86 and the 
major histocompatibility complexes I and II (MHC I and II). CD80 is 
highly expressed in bone marrow-derived macrophages in comparison to 
splenic and peritoneal macrophages. CD86 is relatively evenly expressed 
among these three macrophage types while MHC II is highly expressed in 
peritoneal macrophages, whereas, RAW264.7 hardly express any MHC 
II. MHC I is relatively evenly expressed among bone marrow-derived, 
splenic macrophages and the RAW264.7 cell line [195, 196]. This clearly 
suggests that there is a potential difference between macrophage models 
in their capability of activating T cells. However, one study suggests that 
there is no difference in antigen presentation the between macrophages 
derived from bone marrow, spleen or peritoneum [195].  
Bone marrow derived cells have been shown to express significantly 
higher levels of Il10 and Tgfb than splenic and peritoneal macrophages, 
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whereas splenic macrophages express higher levels of Il6, Il12 and Tnfa. 
However, all three macrophage types expression similar levels of pro-
inflammatory cytokines in response to lipopolysaccharide (LPS) 
stimulation [195]. Compared to primary macrophages, the macrophage 
cell lines IC-21, RAW264.7 and J774.2 display very low response to LPS 
[197]. In order to motivate the use of mouse derived macrophage models 
it is important to demonstrate a phenotypic profile that is relevant for the 
research question, as well as to have an understanding in the difference 
between human macrophages. Unfortunately, there are a limited number 
of studies available on this topic. However, Spiller et al. has compared 
the gene expression profiles between mouse and human bone marrow-
derived macrophages, including the human monocyte cell line THP-1 
[198]. It is one of very few studies that also include the comparison 
between different activation states (naïve, M1 and M2). This study shows 
similarities between mouse and human macrophages as judged by e.g. a 
similar upregulation of Cxcl-10, Cxcl-11, Tnfa and Ccl1 in M1-
macrophages. Despite the similarities, human macrophages are clustered 
together away from the bone marrow derived cells of mice. One of the 
most notorious differences between mouse and human (as well as several 
other species such as rabbit, goat and Syrian hamster) is the difference in 
arginase metabolism.  Human macrophages has been shown unable to 
produce NO from NOS2 in vitro, while undoubtedly being able to 
express NOS2, this is thought to be as a consequence of very specific 
signals that are difficult to reproduce in vitro. This depicts that there are 
interspecies differences in effector function based on metabolic 
indifferences, within these cells [199, 200].  
In mouse adipose tissue, the macrophage pool cannot be replaced solely 
by bone marrow transplantation, indicating that adipose tissue 
macrophages originates from both monocytes and yolk-sac progenitors, 
[201]. The homoeostasis of adipose tissue macrophages are thought to be 
sustained by self-renewal rather than relying on infiltration of circulating 
monocytes [201-203]. In contrast, during obesity there ample evidence 
for increased infiltration of monocytes although self-renewal of adipose 
tissue resident macrophages also increase [204]. Similar to obese adipose 
tissue, growing tumors accumulate primarily bone marrow derived 
macrophages. There is a consensus of the field that the selection of a 
macrophage model should account for the nature and origin, as well as 
phenotype of macrophages in vivo. Therefore, we believe bone marrow 
derived macrophages serve as a suitable model in the experiments of this 
thesis. 
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ENERGY METABOLISM IN ADHERENT CELLS 
The mitochondrial bioenergetics is commonly assessed to identify 
changes metabolic phenotypes in cultured cells. The assessment usually 
includes evaluation of ATP synthesis (directly or indirectly), redox or ion 
homeostasis. These processes are defined by the respiratory steady-state 
conventions (1-5), which were first introduced in a series of five papers in 
1955 [205]. In brief, the main driver of ATP synthesis is the membrane 
potential spanning across the mitochondrial inner membrane, which is 
generated by protons. The energy released from this proton gradient is 
used by the ATP synthase (complex V) to generate ATP. The resulting 
drop in membrane potential is restored by three electron transport 
complexes (I, III and IV), which consumes substrates (NADH) and 
oxygen to transport protons exteriorly to the mitochondrial inner 
membrane. Electrons received from NADH travels through each complex 
and results in a drop in redox potential in each step. When the 
requirement for ATP is low, the proton circuit can instead be uncoupled 
from ATP synthase through proton uncouplers, which for example can 
prevent the formation of reactive oxygen species from single electrons 
[206]. 
The main methods to evaluate mitochondrial function rely thus on 
measurements of oxygen consumption, redox or ion homeostasis. The 
two latter revolves around the use of triphenylphosphonium 
hydroethidine-based dyes (MitoSOX Red, Invitrogen) and cationic 
fluorescent probes using either confocal microscopy or flow cytometry. 
Oxygen consumption is measured by respirometry, for which there are a 
number of methods. The most notable are the use of amperometric O2-
sensors and O2-dependent quenching of porphyrin-based phosphors 
[207]. The latter is utilized in the XF Extracellular Flux Analyzer 
(Agilent, Seahorse Bioscience), using fluorophores sensitive to O2 and H
+
 
which are connected to fiber optic bundles of the sensor cartridge. This 
method has a lower resolution than amperometric O2 sensors and is more 
prone to variation in each measurement. Furthermore, instruments using 
amperometric O2 sensors employ closed air-tight reaction chambers with 
constant stirring, which leads to more accurate substrate delivery, better 
oxygen diffusion and therefore quicker response time and reduced 
background noise. Applications utilizing amperometric O2 sensors (such 
as OROBOROS Instruments) are mainly adapted to isolated 
mitochondria, permeabilized cells and intact cells in suspension, while 
the XF Extracellular Flux Analyzer are adapted to attached cells or 
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mitochondria, and has a higher throughput allowing for screening-based 
applications.  
The XF Extracellular Flux Analyzer was chosen for this thesis work 
because of its high throughput application. The mitochondrial function 
can be assessed using chemicals targeting different pathways in 
metabolism such as oxidative phosphorylation, glycolysis and fatty acid 
oxidation. General mitochondrial function can be measured by the so 
called “Cell Mito Stress Test Kit” that relies on the sequential addition of 
the ATP synthase inhibitor oligomycin, the proton uncoupler carbonyl 
cyanide-p-trifluoromethoxyphenylhydrazone (FCCP), and rotenone 
together with antimycin which inhibit complex I and III, respectively. 
The change in oxygen consumption rate, as required by the electron 
transport chain (complex IV) to maintain the membrane potential (proton 
gradient), are then used to calculate non-mitochondrial, basal and 
maximal respiration as well as ATP turnover, proton leak, coupling 
efficiency and spare respiratory capacity. Basal respiration represents the 
basic cellular ATP demand and proton leak. ATP turnover is estimated 
from the difference between basal respiration and respiration after 
addition of ATP synthase inhibitor (oligomycin), subtracting non-
mitochondrial respiration (observed when the electron transport chain is 
fully inhibited). During ATP synthase inhibition, the electron circuit is 
looped by proton uncoupling (UCP-1) in order to maintain the membrane 
potential [208]. Pharmacologically-induced uncoupling by FCCP 
resembles an artificial energy demand, and is used to evaluate the 
maximal respiration rate. Normal/high mitochondrial function is reflected 
in a high maximal respiration whereas a lower maximal respiration may 
imply mitochondrial dysfunction and a higher reliance on glycolysis. The 
spare respiratory capacity is the difference between maximal and basal 
respiration and indicates how close the cell is to its bioenergetical limit – 
it is thus a measure of the mitochondria’s ability to adapt to a rapid 
increase in energy demand. 
Worth mentioning is that the actual ATP production and proton 
uncoupling are liable to underestimation and exaggeration, respectively.  
This is due to the fact that during ATP synthase inhibition, the membrane 
potential is hyperpolarized which affects the voltage-dependent proton 
uncoupling. In other words, the ATP-synthesis is underestimated 
meanwhile the proton leak is overestimated. This brings the coupling 
efficiency (100 (ATP-production-linked respiration/ basal respiration)) as 
a more useful parameter for mitochondrial function as it reflects 
alterations in both parameters as a whole. The coupling efficiency is 
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therefore likely to change during altered mitochondrial function, and this 
ratio is also internally normalized [206]. 
Lastly, but of importance to the experimental work performed on 
macrophages is the non-mitochondrial respiration.  This is a process 
which historically was discovered in phagocytes, neutrophils and later 
shown in macrophages and was termed “the respiratory burst” [150, 209]. 
The respiratory burst is mediated by NADPH oxidases (NOX1-5, 
DUOX1-2) which consume oxygen to generate reactive oxygen species 
(e.g. during an infection). Reactive oxygen species can also react with 
nitric oxide produced from NOS2-expressing macrophages thus 
producing peroxynitrite. Both nitric oxide and peroxynitrite inhibits 
several mitochondrial electron transport complexes [210]. The non-
mitochondrial respiration may thus reflect on the effector function of 
macrophages. 
LIPID METABOLISM MEASUREMENTS USING 
RADIOLABELED TRACERS 
In this thesis, measurements of lipid metabolism are central. Circulating 
lipid levels reflect lipogenesis, lipolysis, lipid uptake, and lipid absorption 
from the diet [211]. To measure changes in any of these parameters 
separately, one can administrate lipids or glucose labelled with either 
stable or radioactive isotopes. The labeling of a molecule implies the 
substitution of a common atom such as carbon, hydrogen, nitrogen or 
oxygen with an isotope, which results in the formation of a tracer. The 
original molecule is referred to as the tracee. Stable isotopes are used in 
the clinic as they possess a minimal risk on health, but require magnetic 
resonance or mass spectrophotometry. This also allows also for 
simultaneous measurements of  tracer and tracee with high precision as it 
can be used to distinguish between e.g. individual metabolic reactions 
(depending on the molecular composition of the tracer) [212]. However, 
the downside is that magnetic resonance or mass spectrophotometry is 
time consuming, expensive and requires profound sample preparation. In 
this work the radioactive isotopes 
3
H-triolein and 
14
C-glucose has 
therefore been used to measure lipid and glucose uptake as well as to 
estimate fatty acid oxidation and lipogenesis in vivo (
14
C-glucose was 
also used to measure de novo lipogenesis in vitro). These lipid and 
glucose tracers were mixed with Intralipid and administered orally to 
mice, upon blood, tumor and adipose tissue were collected for analysis 2h 
after administration. In general, tissue samples were homogenized in in a 
mixture of chloroform and methanol to separate the aqueous and organic 
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phase. The 
3
H and 
14
C were detected using a liquid scintillation counter. 
The aqueous phase contains water-soluble metabolites. The 
3
H counts in 
the aqueous phase can thus be used to estimate fatty acid oxidation. The 
organic phase contains neutral lipids such as triglycerides and the 
3
H and 
14
C counts represent, therefore respectively, measures of lipid storage and 
de novo lipogenesis.  
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RESULTS AND DISCUSSION 
EXTRA CELLULAR FLUX ANALYZER: 
INTERPRETING OXYGEN CONSUMPTION DATA  
Changes in cellular metabolism play a role in the development of 
pathophysiological conditions such as obesity-related comorbidities, 
autoimmune diseases and cancer. At a cellular level, phenotypic 
switching and metabolic interactions amongst cells are vital in both 
normal conditions during tissue development and remodeling as well as 
in many diseases such as cancer and infection.  
Cellular density and nutrient level: key parameters in 
measurements of mitochondrial function  
In vitro models, such as cell culture where one does not need to deal with 
the complexity of the body, may at a first glance seem to be more 
straightforward and less prone to variability than animal models. 
However, also cell culture models require extensive experience and 
consideration to several confounding parameters such as media 
composition, cellular density and incubation conditions. In other words, 
one needs to pay attention to changes in the microenvironment. 
Moreover, cancer cells are heterogeneous and typically display genomic 
instability, which add additional complexity to consider when designing 
the experimental set up.  
We have used the Seahorse extracellular flux (XF) analyzer (Agilent 
Technologies) to assess mitochondrial function in 3T3-L1 adipocytes 
(Paper I), 3T3-L1 pre-adipocytes, E0771 breast cancer cells and bone 
marrow derived macrophages (Paper II-III). The experimental protocols 
for these measurements had to be defined for each cell type. Agilent 
Technologies encourage users to submit their cell-specific protocols 
online and these protocols can then be accessed in an online database. 
Among the cell lines found in this database are 3T3-L1 adipocytes. 
Nevertheless, to obtain oxygen consumption rates within the appropriate 
range we had to optimize the experimental conditions to work in our 
hands (Paper I).  Moreover, no protocols for assessing E0771 breast 
cancer cells or bone marrow derived macrophages were to be found in 
this database, and these needed thus to be established from scratch.  
One of the most critical parameters in these Seahorse XF analyzer 
experiments is the cellular density that determines the oxygen 
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consumption rates although this also varies between cell types and other 
experimental conditions. The recommendation from the manufacturer 
implies a near confluent monolayer of cells which roughly approximates 
to 100 000 cells per well. Numbers below this value can result in 
inconsistency in readings between probes (discussed later). However, 
numbers beyond this value may lead to nutrient depletion at a faster rate 
that in turn results in cells entering a dormant state where respiration 
decreases. Visually, this shows up as an oxygen consumption rate that 
declines over time and the response to challenges such as oligomycin 
may be low or even absent. Furthermore, such a behavior is also 
commonly seen in cells with extreme metabolic demands such as highly 
proliferative cells. Depletion of nutrients may thus lead to an altered 
metabolism that is not directly related to the type of treatment.  
The optimal cellular density is determined by titration for which the 
outcome should display a linear relationship (determining the range of the 
assay) and this is discussed as one of the key points by Dranka et al 
[213]. In that study, a cell density between 20 and 50000 cells per well 
generated the most reproducible data when myocytes were studied. 3T3-
L1 adipocytes, on the other hand, were seeded at 5000 cells per well to 
allow for the necessary proliferation during the differentiation steps and 
reached a number around 100 000 per well. For instance, we tried 
different β3-adrenergic agonist treatment lengths (20 minutes and 24 
hours) and N-acetylcysteine (30 minutes to 48 hours) which led to the 
obvious and important insight that cells of different types and/or states 
consume nutrients and proliferate at different rates (mature adipocytes do 
however not proliferate at all). Occasionally 3T3-L1 pre-adipocytes 
remain in an undifferentiated and proliferative state after activation and 
this is associated with a completely different metabolic profile as outlined 
below. It is thus critically important to assess the degree of differentation 
prior Seahorse analysis. Moreover, using the same cell density and 
treatment lengths (e.g. C1QTNF3 recombinant protein treatment – Paper 
II) in different cell types may elicit different results on cellular 
metabolism simply because some cell types proliferate and/or consume 
nutrients faster. 
3T3-L1 pre-adipocytes displayed a relatively low oxygen consumption 
rate and low response to oligomycin as well as high inter-plate variance, 
regardless of tested cell densities. This can be interpreted either as a 
consequence of too high cellular density resulting in nutrient depletion, 
which may conclude to re-evaluate the seeding protocol for this particular 
cell line. Moreover, this data can also be interpreted as an increased 
reliance on glycolysis to generate ATP than on oxidative 
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phosphorylation, a phenotype commonly seen in undifferentiated cell 
types such as stem cells and cancer cells that have underwent so-called 
mesenchymal stem cell transition [7, 214, 215]. As discussed above, 
nutrient depletion may however lead to a similar phenotype. Thus, one 
needs to be cautious when drawing conclusions from this type of oxygen 
consumption measurements.   
To study interactions between E0771 breast cancer cells and adipose 
tissue (Paper III), we used the Seahorse XF analyzer in combination 
with co-culture. In the co-culture setting, it is likely that nutrients are 
depleted quicker than in the control (non-co-culture condition). This 
implies that the resultant metabolic profiles need to be evaluated carefully 
as the difference between groups could be either due to metabolic 
interactions (that we aim to study) or to excessive nutrient depletion in 
the co-cultured cells. Therefore, we have analyzed the effect of chamber 
volume and co-culture time in these experiments and found that 2 mL and 
24h culture in a 12-well plate did not lead to increased nutrient depletion 
in co-cultured E0771 breast cancer cells compared to E0771 breast cancer 
cells cultured alone (40 000 cell/well) (Paper III). 
Metabolic plasticity 
The fact that undifferentiated cells typically rely on glycolysis doesn’t 
rule out that they can produce ATP through oxidative phosphorylation. 
Such capability of switching from one metabolic phenotype to another 
can be referred to as “metabolic plasticity”. Metabolic plasticity is 
commonly seen in cancer cells. Such metabolic plasticity may manifest as 
intra- (between wells) and inter-plate (between plates) variation. For 
which the latter has proven to be of the largest concern in oxygen 
consumption rate measurements, although intra-plate variation may also 
be troublesome  [216]. Intra-plate variation may seem to be an unlikely 
problem as established cell lines are supposedly stable. Together with the 
fact that cell culture proves to be a stable environment sustaining less 
factors provoking evolution of cancer cells than what occurs in the 
organism itself. However, this does not out rule that cancer cells 
constantly evolve regardless, and is demonstrated to be problematic in 
most immortalized cell lines, being explained expressed as genetic drift 
sustained by sub-culture  [217]. 
Indeed, during this work (Paper I-III) inter-plate variation has been of 
similar concern as intra-plate variation. Even the slightest difference in 
cellular number between wells may have large effect on respiration since 
E0771 breast cancer cells proliferate extremely fast (Paper II). 
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Furthermore, some cells did not respond to the compounds used in the 
mito stress test, although some cells did. Unresponsiveness to the 
uncoupler FCCP can be interpreted as having a cellular metabolism 
already close to maximal capacity and/or already an uncoupled electron 
transport chain (depending on the basal oxygen consumption rate). 
However, if the basal oxygen consumption rate is low meanwhile not 
responding to FCCP this may infer to at a mitochondrial dysfunction 
and/or increased reliance on glycolysis. A reliance on glycolysis may be 
tested more directly through measurements of the extracellular 
acidification rate (and the glycolysis stress test). Meanwhile 
unresponsiveness to oligomycin may reflect that ATP-production from 
ATP synthase (mitochondria) is not responsible for the observed oxygen 
consumption rate (the electron transport chain may be uncoupled). 
Indifferences in the basal respiration (or ratios in oxygen consumption 
rate between oligomycin and FCCP treatments) is generally interpreted as 
an altered mitochondrial function, however non-responsiveness could 
also be interpreted as a reduced mitochondrial density rather than 
diminished mitochondrial function. Changes in mitochondrial density 
may be of greater concern in certain experimental conditions where 
mitochondrial dysfunction is induced, as this ultimately allows for the 
removal of non-functional mitochondria through mitophagy [218]. In 
certain experimental conditions such as co-culturing adipocytes with 
cancer may inflict such changes. Treatment of C1QTNF3 reduced the 
mitochondrial respiration in macrophages and this is generally interpreted 
as reduced mitochondrial function, but at least in theory the reduced 
respiration could be a consequence of reduced number of mitochondria 
(Paper II). 
The third cell type we have analyzed with Seahorse technology was bone 
marrow derived macrophages (Paper II). For this cell type, we found that 
this methodology gave reproducible results. M1- and M2-activated bone 
marrow derived macrophages displayed their expected phenotype; the 
energy production of M1-like depended primarily on glycolysis whereas 
M2-like used oxidative phosphorylation  (Figure 7) [153]. Furthermore, 
C1QTNF3-induced reduction in mitochondrial respiration was associated 
with increased glycolysis i.e. the reduced respiration in the experimental 
setting is unlikely to result from e.g. increased proliferation associated 
with nutrient deprivation in C1QTNF3-treated cells (Paper II). 
Nevertheless, inter-plate variation is of great concern also when studying 
macrophages. Bone marrow derived macrophages are prone to become 
more M2-like during the differentiation (and activation phase) as 
reflected by their gene expression profile where M1-like activated cells 
also display M2-markers [219]. In this thesis, the metabolic profile was, 
 43 
 
however, clearly different between M1- and M2-activated macrophages. 
We believe that the response to C1QTNF3 varies dependent on the 
degree of macrophage differentiation. Such scenario is unfortunately 
difficult to control for since cells from different batches may reach 
slightly different level of differentiation despite the same treatment 
protocol, leading to inter-plate variation. For instance the degree of 
macrophage differentiation may affect metabolic plasticity leading to 
different response to C1QTNF3 treatment [220]. In general, the criteria 
which was used to determine successful or adequate macrophage 
differentiation was based on M2-like macrophages having a slightly 
higher basal metabolism and spare respiratory capacity than naïve, as 
described elsewhere [221]. 
Research indicate that cancer cells are able to quickly re-adapt to nutrient 
deprivation by changing gene expression and metabolic profile to 
compensate the metabolic needs, similarly such variation is seen in the 
tumor microenvironment, and thus is of high consideration when 
comparing different cell lines and primary derived cells [222]. However, 
E0771 breast cancer cells did not seem to have this ability in vitro: In the 
fatty acid oxidation assay of E0771 breast cancer cells (Paper III), the 
basal respiration decreased with time likely as a consequence of the very 
low glucose levels in the fatty acid oxidation assay media which were 10 
times lower than the glucose levels in the Mito stress test buffer. Thus, 
cellular metabolism in cell culture is sensitive to media composition 
where different media elicit rewiring of metabolic pathways and 
alternated metabolomic profiles or simply leads to nutrient deprivation 
(which is the most likely scenario in this case).   
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Figure 7. The metabolic profiles of naïve, classically and alternatively activated 
macrophages in normal conditions and when challenged by C1QTNF3 recombinant 
protein for 24 hours. As depicted by the graphs, M1 (i.e. classically) activated 
macrophages (B) presented with an energy profile void of mitochondrial respiration, 
unlike naïve and M2 (alternatively activated) macrophages, (A) and (C) respectively, 
which displayed normal mitochondrial function. C1QTNF3 led to a decreased 
mitochondrial respiration. 
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Technical variance 
Intra- and inter-plate variance is not only reflected upon the experimental 
conditions as defined by the user but also by technical issues. During 
each experiment there have been a number of wells that don’t respond to 
oligomycin and FCCP. These wells are typically located on the edges of 
the cell culture plate. This phenomenon is well known and may be a 
consequence from temperature fluctuations as there are fewer 
neighboring media-filled wells. Essentially this reduces the number of 
replicates in each treatment group; therefore, in order to maximize the 
number of replicates, the number of treatment groups was limited. 
Similar non-responsiveness has been observed in wells that initially were 
responding to treatment (oligomycin) but then failed to respond to FCCP. 
This was interpreted as the sensor being blocked by air bubbles or 
cellular debris that may be generated during running of the assay (and not 
as a consequence of a retracting sensor between each measurement as it 
never leaves the media). Although the sensor continues to measure 
oxygen this does not out rule that the sensor was faulty from the 
beginning, which makes it sometimes difficult to distinguish between 
biological and technical outliers. The technical aspects affecting 
reproducibility and reliability of every probe (of each sensor) can be 
indulged elsewhere, and may partly serve as an explanation to the data 
variability [223]. 
Conclusions 
Seahorse XF analyzers are more and more used to assess mitochondrial 
function and glycolysis of cultured cells, isolated mitochondria and even 
of tissue pieces. The method allows for comprehensive drug screening in 
different scenarios where long- and short-term treatments effect of 
compounds can be studied. However, great cautiousness has to be kept in 
mind while designing studies, as cells can display metabolic plasticity 
leading to different results due to timing, cellular density and treatment 
strategy. Cells not displaying the expected response to oligomycin and 
FCCP may be considered as technical outliers, but such unresponsiveness 
may originate from starvation, preference for glycolysis and/or a 
redirected metabolite flow into pathways required for biosynthesis due to 
in vitro treatment conditions. This suggests that it may be easier to 
analyze differentiated cell with this technology than undifferentiated stem 
cell-like cells or stem cells. Thus, using extracellular flux analyzers for 
metabolic phenotyping requires deep knowledge about the properties of 
the cells of interest including relevant confounding factors.  
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C1QTNF3 IN TUMOR PROGRESSION: 
MACROPHAGE IMMUNITY IN THE ADIPOSE 
TISSUE-TUMOR INTERFACE 
During the past decade, cancer treatment has had a crude appearance, 
essentially relying on the utilization of chemo- and radiation therapy. The 
direction of cancer treatments was revolutionized by the idea of targeting 
immunity. This was demonstrated by the first generation of immune-
checkpoint inhibitors, which act by blocking certain receptor and ligand 
interactions involved in pathways such as activation and effector function 
of immune cells. These pathways are in turn crucial for the development 
of self-tolerance allowing the tumor to remain undetected by the immune 
system (i.e. immune evasion). The first generation of antibody-based 
immunotherapies, CTLA4, PD-1 and PD-L1, have been used to inhibit 
de-activation and programmed cell death of T cells [25]. Immune cell 
activation and effector function exhibit a high level of complexity as well 
as diversity, which to large extent is defined by the regulation of cellular 
metabolism [30]. Cellular metabolism is a crucial aspect, not only for 
activation and effector function but also for immune regulation including 
antigen presentation, clonal expansion of T cells, differentiation and 
wound healing [30]. Local cues in the microenvironment act as signals to 
determine the immune landscape, however, immunity itself can be 
regulated by cellular metabolism by means of forced reprogramming (i.e. 
tumor associated cell types such as cancer associated fibroblasts, 
macrophages and lymphocytes) or metabolite restriction (nutrient 
competition) as a consequence of tumor interaction. Similarly, excess of 
nutrients such in obesity-related disorders is suggested to exert a role in 
immunity via cellular metabolism. Immune cell infiltration has been used 
to define the tumor microenvironment into different immune infiltrate 
classes, although this classification is based on low-resolution sources 
such as bulk tissue microarrays and immunohistochemistry, whereas 
tumor-derived metabolic intermediates can be used to associate the 
immune cell infiltrate based on the metabolic status [25, 224]. In obesity, 
the breast cancer microenvironment can be dysregulated both as a 
consequence from systemic alterations such as hyperinsulinema and 
hyperglycemia and due to local changes in adipose tissue that involve low 
grade chronic inflammation associated with an altered release of 
adipokines/cytokines. In general, three major links between obesity and 
increased tumor progression have been proposed; systemic endocrine 
alterations that involve 1) the insulin-like growth factor 1 axis, and 2) 
altered adipokine levels (leptin and adiponectin) [225] and 3) increased 
estrogen levels in postmenopausal obese women. Furthermore, obesity is 
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associated with an increased risk of developing hormone negative 
(aggressive subtype) in premenopausal women [8, 226]. There is however 
knowledge gap as for how lean and obese adipose tissue can affect tumor 
progression through local interactions.  
Finding proteins in the adipose tissue-tumor interface 
In order to identify novel adipose tissue-derived factors potentially 
important in tumor progression and/or adipose tissue functionality, we 
compared the gene expression profiles between E0771 breast cancer-
associated and control mammary/inguinal adipose tissue in syngeneic 
lean and high fat diet-induced obese female mice (Paper II). This 
approach revealed a marked upregulation of C1qtnf3 along with several 
chemokines and macrophages makers in tumor associated adipose tissue, 
and this upregulation was enhanced by obesity (Figure 8). Importantly, 
increased C1qtnf3 mRNA expression was associated with increased 
inguinal adipose tissue release of C1QTNF3 protein although serum 
C1QTNF3 levels (about 100 ng/ml) were similar between groups. 
Moreover, the serum levels were approximately 6-10 times lower than the 
amount secreted from 30 milligram adipose tissue in 1 mL media (after 6 
hours), suggesting a more prominent role as an auto- or paracrine 
mediator than as a classical hormone. C1QTNF3 may thus be similar to 
inflammatory cytokines that typically are released in response to tissue 
damage and/or infection and act locally, although low levels can be found 
in the circulation. At this stage, it was difficult to interpret what the 
measured C1QTNF3 levels mean, but most cytokines are very potent and 
act at low concentrations. Unlike most cytokines however, C1QTNF3 has 
previously been shown to exert anti-diabetic and anti-inflammatory 
effects as well as mediating effects on oxidative phosphorylation [59, 61, 
62]. Whereas, very little is known about its potential role in tumor 
progression or macrophage regulation.  
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Figure 8. The C1qtnf3 gene expression was upregulated in tumor-associated inguinal 
white adipose tissue (IWAT) and this effect was enhanced by diet-induced obesity. 
 
C1QTNF3 regulation in mouse adipose tissue 
The gonadal adipose tissue expression and circulating levels of 
C1QTNF3 are increased in genetically obese Ob/Ob mice whilst 
circulating levels are reduced in diet induced obese mice [58-60]. 
However, very little is known about Ciqtnf3 gene expression in different 
adipose depots. We have shown that gonadal and mesenteric adipose 
tissues have a higher C1qtnf3 expression than inguinal adipose tissue. 
However, the major part of the gene expression was not attributable to the 
adipocytes, but rather originating from cells of the stroma vascular 
fraction and this expression was enhanced by obesity (at least in inguinal 
white adipose tissue, whereas other depots were not examined). 
Moreover, the C1qtnf3 expression was relatively high in 3T3-L1 pre-
adipocytes, while very low levels were detected in peritoneal 
macrophages and E0771 breast cancer cells. Interestingly, 1-week high 
fat feeding of male mice led to a dramatic upregulation of the inguinal 
adipose tissue expression of C1qtnf3 and the pan-macrophage marker 
F4/80. This is a time point where significant tissue remodeling occurs in 
inguinal adipose tissue as shown by loss of collagenous septa [227] 
associated with recruitment of CD206
+
-macrophages (Vujičić et al, 
unpublished observation in the lab). Based on these observations in breast 
cancer- and high fat diet-challenged conditions, we hypothesized that 
C1QTNF3 played a role in macrophage recruitment to inguinal adipose 
tissue. Such effect on macrophages may be at the level of chemotaxis, 
proliferation, differentiation and/or activation as discussed in the 
following section.  
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C1QTNF3 in macrophage metabolism 
C1QTNF3 has been shown to regulate metabolism and to be expressed by 
metastasis-associated fibroblasts. These observations, in combination 
with our findings that the inguinal adipose tissue expression of C1qtnf3 is 
induced by breast cancer and by 1-week high fat diet feeding, and is 
positively correlated with macrophage markers, suggest that C1QTNF3 is 
involved in macrophage regulation through metabolic re-programming 
(Paper II). Macrophages play a key role both in adipose tissue during 
remodeling (e.g. expansion) and in tumor immunity. Thus, we 
hypothesized that the outcome of such a mechanism can be involved in 
tumor rejection or is exploited by the tumor itself for immune evasion. 
Alternatively, the increased C1QTNF3 levels are unrelated to tumor 
immunity and instead they may play a role in the adaptive adipose tissue 
remodeling that occurs in response to high fat diet-induced adipocyte 
expansion or increased pressure from a growing tumor. Immune evasion 
refers to one of the Three E’s of immunoediting; to avoid elimination, 
achieve equilibrium or to escape that occurs at different stages of tumor 
progression, for which the immune evasion (escape) most often relate to 
later stages [228]. Tumor-associated macrophages, which typically are 
M2-like, are in general associated with enhanced tumor progression (as 
outlined in the introduction). Furthermore, data have also shown that 
tumors can be recognized by the immune system, and that the 
accumulation of tumor infiltrating lymphocytes in fact serves to prevent 
tumor progression as opposed to serve the tumor [229].  
In order to evaluate this hypothesis and to thus elucidate if C1QTNF3 
play a role in macrophage regulation and tumor progression, both in vivo 
and in vitro techniques were employed. C1QTNF3 recombinant protein 
was given to E0771 breast cancer cells, 3T3-L1 (pre- and mature 
adipocytes) and bone marrow derived macrophages (naïve, M1 and M2-
like) to investigate whether C1QTNF3 affects metabolism. C1QTNF3 did 
not affect oxidative phosphorylation of either E0771 breast cancer cells 
or 3T3-L1 adipocytes. There was however a small increase in ATP-
production and coupling efficiency in C1QTNF3-treated 3T3-L1 pre-
adipocytes, but the biological significance of such a small effect can be 
questioned. These data do not exclude that there are changes in fatty acid 
oxidation or glycolysis, i.e. substrate specificity or pathway rerouting 
(including anaplerotic reactions), but these parameters were not 
measured. Interestingly, C1QTNF3 diminished several parameters of the 
oxidative phosphorylation in all three macrophages subtypes (naïve, M1- 
and M2-like), where the most prominent effect was seen in M2-like 
macrophages (Figure 7). These data suggest that C1QTNF3 enhances 
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M1-like macrophage polarization or activation. To evaluate this 
assumption, the glycolytic rates (extracellular acidification rates, ECAR) 
were measured in in naïve and M2-like macrophages. Indeed, C1QTNF3 
treatment led to increased glycolysis. In further support of this 
metabolic/immunological reprogramming, C1QTNF3 treated M2-like 
macrophages displayed an increased expression of M1-like macrophage 
markers (Nos2 and Il-1b). The modulation of effector function through 
metabolism after activation (metabolic plasticity) was also studied; 1h 
C1QTNF3 treatment of M2-like macrophages reduced the maximal 
respiration and the spare respiratory capacity indicating that C1QTNF3 
has an impact on metabolism even after M2-activation. As judged by 
Western blot analysis, this effect appeared to involve ERK- and possibly 
Akt-signaling, but not NFB-activation (Paper II).  
There have been several reports on tumor associated macrophages 
showing the ability of M2-like to repolarize into M1-like whereas, a non-
reversible mitochondrial dysfunction in M1 macrophages has been 
identified as a mechanism preventing M2 repolarization [220, 230]. 
Based on our in vitro data, C1QTNF3 may be involved in a tumoricidal 
response through its M1-polarizing effect on M2 macrophages. 
C1QTNF3-mediated immunity and role in tumor progression 
Bone marrow derived macrophages undergo phenotypical changes 
towards a pro-inflammatory phenotype when subjected to C1QTNF3 
recombinant protein. This was evident from reduced mitochondrial 
metabolism and increased glycolysis of naïve and M2-like activated 
macrophages, as well as from an M1-like gene expression profile. In 
order to test whether the increased local C1QTNF3 levels affects tumor 
progression in vivo, obese E0771 breast cancer implanted mice received 
either C1QTNF3 or isotype control antibodies. We hypothesized that 
blockage of C1QNTF3 inhibits the formation of M1-like macrophages in 
the tumor-adipose tissue interface possibly increasing tumor progression. 
We found that antibody-mediated neutralization of C1QTNF3 protein 
decreased tumor-induced infiltration of macrophages in inguinal adipose 
tissue (Figure 9). However, no effect was seen on neither tumor weight, 
nor on the percentage of tumor-associated macrophages, macrophage 
polarization in tumor, tumor associated inguinal white adipose tissue, and 
spleen (Paper II). As judged by FACS analysis of CD206 and NOS2 
expressing macrophages (CD11b
+
F4/80
+
 cells), the effect of C1QTNF3 
on macrophage polarization observed in vitro could thus not be 
reproduced in vivo. One possibility is that the variability between mice 
was too large to allow for detection of a possible decrease in the already 
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very low percentage of NOS2
+
-macrophages in the C1QTNF3 antibody-
treated group. Another explanation for this discrepancy between in vitro 
and in vivo conditions is that certain molecules can exert different 
functions on macrophage infiltration and polarization as a consequence of 
temporospatial effects such as heterogeneous microenvironment 
depending on tumor size and stage. An altered microenvironment may 
also induce post-translational modification that affects the biological 
function of a given cytokine [231].  For instance, CCL2 has been shown 
to act both as a chemoattractant and a regulator of macrophage 
polarization in tumors and in obese adipose tissue. Removal of CCL2 
results in increased M1-like polarization of human macrophages, and 
similarly as shown by another study, CCL2 stimulation caused peripheral 
blood cells to polarize towards and M2 phenotype [232, 233]. However, 
neutralization of CCR2 (the receptor for CCL2) reduces the recruitment 
of M1-like macrophages to obese gonadal adipose tissue [234]. 
Furthermore, macrophage recruitment and polarization towards M1 in 
adipose tissue during obesity is attributable not only to the CCL2-CCR2 
axis, but also to e.g. the CCL5-CCR5 axis. Inactivation of the latter 
resulted in a reduced number of adipose tissue macrophages, whereas, 
recruited macrophages expressed M2-like phenotype [235]. Thus, there 
are many factors that can affect macrophage polarization and some 
factors may even display different function dependent on the (patho-) 
physiological setting. It is therefore not improbable that the effect of 
C1QTNF3 on macrophages depends on the microenvironment.  
In most mouse models of obesity, there is an increased infiltration of 
macrophages in adipose tissue and these macrophages adopt a pro-
inflammatory profile (M1) [236]. In this study (Paper II), diet-induced 
obesity alone did however not have any effects on macrophage 
infiltration and polarization in inguinal adipose tissue in females, which 
may reflect both the studied adipose tissue type and sex differences. 
Macrophage infiltration is less frequent in inguinal than in gonadal 
adipose tissue and females display in general a lower infiltration of 
macrophages than males [237]. Unlike healthy lean conditions, obesity 
was however linked to an increased macrophage infiltration in tumor 
associated inguinal adipose tissue compared to control inguinal adipose 
tissue (Paper II). Moreover, tumors in obese animals showed a trend 
towards increased accumulation of macrophages compared to lean 
animals and these macrophages displayed an increase M2 and M1-M2 
polarization. Given the large body of research showing that obesity 
causes an M1-like polarization, this effect may appear surprising. 
However, more recent studies show that obese adipose tissue 
macrophages are both of M1 and M2 type, associated with a metabolic 
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profile expressing both glycolysis and oxidative phosphorylation which 
can be interpreted as more M2-like than strictly M1-like [238-240]. 
Moreover, our data are however in line with a study by Galván et al. 
showing that obesity increases the infiltration and M2-polarization of 
tumor associated macrophages in the context of androgen-sensitive 
prostate cancer [241]. Thus, obesity may promote tumor progression 
through increased M2-like polarization of tumor associated macrophages 
although a potential causal link between obesity, M2-polarization and 
increased tumor size remains to be established. 
Conclusions 
Meta-analysis has suggested that obesity is correlated with a higher 
incidence as well as more aggressive cancer types. Moreover, adipose 
tissue itself has been shown to serve as an environment of which cancers 
prefer to metastasize. The results presented in paper II suggest that 
breast cancer-induced increase in inguinal adipose tissue C1QTNF3 
levels increase macrophage recruitment. Moreover, we observed that 
C1QTNF3 exert potent effects on macrophage metabolism and 
polarization in vitro; upregulating the M1 phenotype characteristics such 
as decreased oxidative phosphorylation and increased glycolysis. In 
contrary to the main hypothesis, there was however no effect of antibody-
mediated C1QTNF3 neutralization on macrophage polarization and 
tumor progression in vivo. We believe that the differences in the 
microenvironment between the in vitro and the in vivo condition may 
serve as explanation for the different outcomes. While possible anti-
metastatic effects of C1QTNF3 remain to be elucidated, the current data 
suggests that C1QTNF3 only plays a modest role in tumor immunity. On 
the other hand, C1QTNF3 may play a key role in the physiological 
remodeling of subcutaneous adipose tissue in the context of diet-induced 
weight gain – a phenomenon that is currently being investigated in our 
laboratory.  
 
Sex-mediated differences in the immune response play a role in both 
human and murine models of disease. In our experimental setting, 
C1qtnf3 gene expression in adipose tissue was however comparable 
between male and female mice. Given the sex differences in fat 
distribution, metabolism and immune responses, the effects of C1QTNF3 
is likely to be different between male and females, but this remains to be 
further elucidated in models of both of obesity and tumor progression.  
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Figure 9. Obese mice orthotopically implanted with E0771 breast cancer were treated 
with an antibody to neutralize the effect of C1QTNF3 protein or isotype control antibody. 
Removal of C1QTNF3 resulted in a reduction of (A) total (CD11b+F4/80+) macrophages 
in tumor associated adipose tissue, but there was no effect of C1QTNF3 neutralization on 
(B) tumor size. 
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THE TUMOR GROWTH PROMOTING EFFECT OF 
ADIPOSE TISSUE IS ASSOCIATED WITH 
INCREASED DE NOVO LIPOGENESIS IN THE 
TUMOR 
 
The stimulating effect of adipose tissue on tumor progression is not only 
a consequence from e.g. alterations in the immune response, but may also 
take root from metabolic symbiosis between cancer cells and 
adipocytes/adipose tissue. Altered energy metabolism has been described 
as an emerging hallmark of cancer [242]. In brief, this refers to 
reprogramming of the cellular energy metabolism to sustain e.g. the rapid 
proliferation of cancer cells. The Warburg effect is one example of such 
metabolic reprogramming:  in the 1920s Otto Warburg demonstrated how 
cancer cells take up large amount of glucose and converts it to lactate 
even under aerobic conditions. Although the Warburg effect often refers 
to the pathological condition of tumors, it occurs also in normal tissue 
and activated immune cells, where there is a great need to generate a 
rapid bursts in energy for functionality [243, 244]. The Warburg effect is 
also described in the so-called lactate shuttle hypothesis, in which cells 
within a tissue display a symbiotic relationship; cells that increase aerobic 
glycolysis shuttle lactate to cells that rely on oxidative phosphorylation. 
Nowadays, it is known that metabolic reprogramming in cancer (as well 
as in e.g. immune cells) also includes other pathways such as increased 
glutaminolysis and lipogenesis. 
 
Adipose tissue is a metabolically active tissue that may provide tumors 
with fatty acids that are essential for growth, proliferation and survival of 
cancer cells [245]. Indeed, tumors have been proposed to engage in such 
metabolic relationships to access lipid content of adipose tissue, 
highlighting both the existence of cancer associated adipocytes, as well as 
fibroblasts mediating such a communicative relationship [114, 124, 125, 
142, 246, 247]. Mechanistically, there is little evidence on how this 
relationship is established, and our aim (Paper III) was to elucidate the 
local effect of adipose tissue on tumor metabolism and progression 
(metabolic programming) focusing on tumor uptake of exogenous lipids 
(adipocyte lipolysis and from the diet) and de novo lipogenesis from 
glucose.  
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Metabolic characterization: fatty acid metabolism in E0771 
breast cancer 
E0771 breast cancer would, based on its triple-negative subtype, be 
associated with a profile towards increased utilization of exogenous lipids 
and reduced de novo lipogenesis [134]. Although molecular classification 
has been shown to be a promising element, it is important to realize that 
such a classification is not trivial and may not accurately reflect the 
functionality of all breast cancers within a given subtype. Thus, E0771 
breast cancer was characterized with respect to its ability to mobilize and 
use exogenous fatty acids, as well as for de novo lipogenesis using both 
in vitro and in vivo models. E0771 breast cancer cells were transplanted 
both ecto- and orthotopically (under the skin outside adipose tissue and 
within mammary/inguinal adipose tissue where breast cancer naturally 
grows) as opposed to the experimental design used in paper II where 
only orthotopic tumors were studied. Tumors within adipose tissue grew 
4.5-fold larger than ectopic tumors and the progression was further 
enhanced by obesity; orthotopic and ectopic tumors of obese mice grew 
respectively, 2- and 3-fold larger than in lean mice (Figure 10). These 
data suggest that adipose tissue plays in important role in tumor 
progression, at least for this type of tumor. Furthermore, the enhanced 
growth in obesity suggests that disrupted adipose tissue functionality 
further enhances tumor progression although we cannot disregard the pro-
tumorigenic effect of e.g. the dietary lipids, hyperglycemia and 
hyperinsulinemia. 
 
 
 
 
 
 
 
Figure 10. Illustrates the tumor growth of ortho- and ectotopically transplanted tumors. 
Orthotopic tumors were implanted in adipose tissue, associated with enhanced tumor 
growth compared to ectopic tumors. Obesity increased the tumor growth in both 
orthotopic and ectopic tumors. 
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Animals harboring tumors for two weeks displayed increased lipolysis as 
determined by their serum free fatty acid levels. In general, increased 
lipolysis is a sign of cancer-associated cachexia, but mice harboring 
E0771 breast cancer tumors did not display any weight or fat mass loss. 
Cachexia in humans, is a phenomenon that usually occurs at later stages 
of chronic disease and in cancer types other than breast cancer such as 
gastric and pancreatic cancer, whereas, affecting 50% of all patients 
suffering from cancer [248, 249]. Thus, it is possible that E0771 breast 
cancer, albeit being able to induce lipolysis, requires a longer period than 
two weeks in order to induce measurable cachexia. No metastatic lesions 
in lungs or other peripheral organs were found, henceforth the model 
could thus be considered to represent early stages of breast cancer. 
To further characterize the extent of the lipolytic capability of E0771 
breast cancer cells, we compared the ability to induce lipolysis between 
different breast cancer cell lines in vitro. To this end, 3T3-L1 adipocytes 
were treated with cancer-conditioned media for 24 hours upon the 
resultant glycerol levels in the media was measured. In line with our in 
vivo data, E0771 breast cancer cells secrete soluble mediators that induce 
lipolysis to a larger extent than other breast cancer subtypes. These data 
are in agreement with a model where triple negative breast cancers, such 
as E0771 breast cancer, thrive on exogenously derived fatty acids 
although it is not necessarily so that a lipolysis-inducing tumor is able to 
take up and use exogenous lipids.  
Next, radiolabeled lipid and glucose tracers were used to compare lipid 
and glucose uptake, fatty acid oxidation and lipogenesis between 
orthotopic and ectopic tumors. We found that orthotopic tumors take up 
more lipids and glucose (although the total glucose uptake difference 
didn’t reach significance, p=0.06) and that this increased uptake largely 
was explained by increased lipogenesis as judged by the [
3
H]-triolein and 
the [
14
C]-glucose counts in the organic phase (Figure 11). This indicated 
that orthotopic tumors both take up more exogenous lipids and synthesize 
more (neutral) lipids from glucose (de novo lipogenesis). Orthotopical 
tumors also displayed an increased expression of Fasn, which further 
supports increased de novo lipogenesis in orthotopic compared to ectopic 
tumors (Paper III). 
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Figure 11. Radiolabeled tracers (glucose and triolein) administered by force feeding was 
used to determine glucose and lipid utilization in ortho- and ectopic tumors. The 
separation of the sample using organic phase separation allows for the quantification of 
neutral lipids storage and water-soluble metabolites. (A) The lipid uptake was higher in 
orthotopic than in ectopic tumors, and there was a similar strong trend for glucose uptake. 
(B) The counts in organic phase represent neutral lipids; orthotopic tumors have a higher 
lipid capacity and a higher glucose-dependent de novo lipogenesis than ectopic tumors. 
(C) The similar lipid and glucose counts in the aqueous phase of orthotopic and ectopic 
tumors indicated that catabolic processes, such as fatty acid oxidation, was not affected by 
the anatomical location of the tumor.  
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Fatty metabolism in vitro 
Thus, adipose tissue-associated E0771 breast cancer tumors displayed 
increased uptake of lipids and increased de novo lipogenesis compared to 
ectopic E0771 breast cancer tumors. Whether this difference can cause or 
simply is a consequence from the enhanced tumor progression of 
orthotopically growing tumors is unknown. Therefore, the possible 
effects of adipose tissue on tumor metabolism in vitro were investigated. 
In a series of Seahorse XF Analyzer experiments in combination with co-
culture of E0771 breast cancer cells and inguinal adipose tissue, we 
determined that tumor cells co-cultured with adipose tissue display an 
increased oxidative phosphorylation whereas the preference for 
glycolysis was reduced (i.e. diminished Warburg effect) (Figure 12). 
Elevated lactate levels can inhibit glycolysis in T-cells and in alveolar 
epithelial type II cells [250, 251] and we may have a similar mechanism 
at play here: adipose tissue releases large amounts of lactate that can be 
taken up by the tumor and thereby block the conversion of pyruvate to 
lactate through feedback inhibition and/or to serve as substrate for energy 
production or lipogenesis. Moreover, a reduced extracellular acidification 
rate may not necessarily mean that ATP-production from glycolysis is 
reduced.   
A reduction in glycolysis could possibly also be mediated by increased 
fatty acid oxidation as consequence from increased fatty acid levels in the 
presence of adipose tissue (although our in vivo tracer data did not 
suggest such a mechanism). Utilizing the Palmitate-BSA Fatty acid 
oxidation Substrate kit, we determined that the use of endogenously 
derived fatty acids was not of a preference, whereas the use of exogenous 
derived fatty acids was reduced in the interface of adipose tissue. In 
contrast to in vivo results where there was no difference in catabolism of 
exogenously derived fatty acids. However, we believe that these in vitro 
data do not accurately reflect the metabolic symbiosis between adipose 
tissue and cancer cells in a more physiological setting. Rather the low 
glucose levels in this assay may put these rapidly dividing cells in a 
dormant state (as discussed previously). It is also possible that the rapid 
proliferation seen in vitro relies on high de novo lipogenesis, and fatty 
acids oxidation and synthesis are unlikely to occur in the same cell at the 
same time. In vivo, a tumor may well be heterogeneous where some cells 
engage in lipogenesis while others in fatty acid oxidation dependent on 
e.g. their stage and oxygenation.   
In line with the in vivo data, adipose tissue co-culture triggers increased 
de novo lipogenesis from glucose in E0771 breast cancer cells (Figure 
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12E). Acetyl-CoA is an essential substrate for de novo lipogenesis and 
can be generated from the citric acid cycle. Lactate has been proposed to 
be utilized directly in lipogenesis, in both bovine and rat adipose tissue in 
1981 and 1974 respectively. Thus it is possible that adipose tissue derived 
lactate can be utilized to generate Acetyl-CoA possibly feeding into the 
citric acid cycle and thereby increasing oxidative phosphorylation and/or 
feeding into the lipogenic pathway [252, 253]. Such effect of lactate was 
not measured in this study, but could be an interesting aspect to analyze 
in the future. However, the effect of lactate treatment on glucose-
mediated lipogenesis was examined, and we found that lactate is a 
possible mediator of the adipose tissue-induced increase in de novo 
lipogenesis of E0771 breast cancer cells (Figure 12). Thus, we have 
proposed that exogenous lactate reduces the conversion of pyruvate to 
lactate and thereby increases the use of glucose for lipogenesis. 
Alternatively, E0771 breast cancer cells is able to oxidize lactate via 
mitochondrial lactate dehydrogenase (a possible metabolic pathway, 
reviewed in [254]), thereby glucose is spared and can be used for 
lipogenesis. Based on these data, we have hypothesized that E0771 breast 
cancer tumors associated with adipose tissue refrains from the Warburg 
effect and instead thrive on lactate produced by adipose tissue. However, 
this hypothesis remains to be fully evaluated using e.g. lactate tracers and 
additional Seahorse extracellular flux analyses. 
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Figure 12. Extracellular flux analysis was performed to characterize changes in the 
metabolic profile of E0771 breast cancer cells with or without 24h inguinal white adipose 
tissue co-culture. Mito stress test was performed by the sequential addition of oligomycin 
(O), FCCP, rotenone and antimycin (R/A). Similarly, the fatty acid oxidation utilizes the 
mito stress test with the exception of pre-treatment with etomoxir (Eto, carnitine 
palmitoyl transferase-1) inhibitor and acute addition of either BSA control and 
palmitate:BSA. The glycolysis stress test was performed by the sequential addition of 
glucose (G), oligomycin (O) and 2-deoxyglucose (2-DG, which is phosphorylated into 2-
deoxyglucose-6-phosphate and trapped intracellularly). (A) Co-culture resulted in a 
marked increment in oxidative phosphorylation associated with (B) reduced glycolysis. 
(C) Oxidative phosphorylation can be associated with increased usage of fatty acids via 
fatty acid oxidation, but in this experimental setting there was no response to etomoxir in 
BSA control conditions suggesting zero oxidation of endogenous fatty acids. However, 
co-cultured E0771 breast cancer cells presented with a lower basal respiration suggesting 
that the competition for nutrients makes co-cultured E0771 cells more “dormant” than 
E0771 breast cancer cells cultured alone at these low-glucose conditions. (D) As judged 
by the etomoxir response, E0771 breast cancer cells co-cultured with inguinal adipose 
tissue did not oxidize exogenous fatty acids while E0771 breast cancer cells cultured 
alone appears to oxidize a small amount of exogenous lipids. However, this fatty acid 
oxidation is likely on expense of a reduced glucose oxidation since the respiration with 
palmitate is not higher than without palmitate.  E0771 breast cancer cells either (E) co-
cultured with adipose tissue or (F) treated with 25 mM lactate for 24h uses more glucose 
for de novo lipogenesis than control cells as indicated by glucose counts in the organic 
phase.  
 
Inhibition of fatty acid metabolism and tumor progression 
E0771 breast cancer tumors induced lipolysis and adipose tissue-
associated E0771 breast cancer tumors displayed increased uptake of 
lipids. We therefore tested the effect of the lipolysis inhibitors (acipimox 
or atglistatin) on E0771 breast cancer tumor growth, but found no 
significant effect on tumor growth. This lack of effect is perhaps not 
surprising given the high capacity for de novo lipogenesis of E0771 
breast cancer cells. Somewhat surprisingly, however, treatment with the 
lipogenesis inhibitor Fasnall led to an initial increase in E0771 breast 
cancer tumor volume in vivo and increased E0771 breast cancer 
proliferation in vitro.  
Tumors are suggested to show a high metabolic plasticity during stress, 
for example the propensity for high lactate production from glucose can 
be alleviated by increased glutaminolysis when glucose availability is 
scarce [255]. Moreover, cancer cells are known to fine-tune their lipid 
metabolism under stressful conditions to sustain proliferative capacity 
and to overcome nutrient competition with other cells such as immune 
cells [256, 257]. Similarly, inhibition of lipolysis may lead to increased 
lipogenesis, and vice versa. This is not to be confused with anaplecrotic 
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flux as with glutaminolysis, but rather as metabolic plasticity. To test this 
hypothesis, radiolabeled tracers can be used to investigate the effect of 
lipolysis or lipogenesis inhibitor in mice on tumor metabolism as a part of 
determining the metabolic plasticity in lipid metabolism. 
Conclusions 
The elegance of Otto Warburg’s paradigm, where he described increased 
aerobic glycolysis in cancer cells, was later described (in the lactate 
shuttle hypothesis) to occur as part of metabolic interplay between cells 
of the same tissue. Thus, the theory of metabolic symbiosis was born and 
serves also as a model for how such interactions can occur between 
normal and malignant cells [258]. It has been proposed that tumors can be 
characterized based on their metabolic preference but also on their 
metabolic interactions with the microenvironment. Bases on gene 
expression analysis, hormone receptor negative breast cancer subtypes 
have been suggested to upregulate their exogenous uptake of fatty acids. 
The data presented here demonstrate however that the triple-negative 
E0771 breast cancer displayed increased lipogenesis when implanted 
orthotopically, associated with enhanced growth, compared to ectopically 
implanted tumors. This increase in lipogenesis occurs despite significant 
uptake of exogenous lipids. Thus, the microenvironment is critically 
important for the metabolic behavior of the tumor. It is possible that 
obese adipose tissue is an even more tumor-promoting environment than 
lean adipose tissue. For instance, the increased lactate production of 
obese adipose tissue may be utilized in metabolic pathways of the tumor 
and also promote tumor progression indirectly through e.g. 
immunosuppressive effects by compromising the function and assembly 
of immune responses against tumors [259]. For instance, lactate 
stimulates the formation of immunosuppressive myeloid derived 
suppressor cells, stabilize HIF1A to drive M2-like macrophage 
polarization and inhibiting the cytolytic activity of natural killer cells.  
However, the exact impact of obesity on the tumor-promoting effect of 
adipose tissue warrants further investigations.  
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